<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Stem Cell Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Stem Cell Res Ther</journal-id><journal-title-group><journal-title>Stem Cell Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1757-6512</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">37143147</article-id><article-id pub-id-type="pmc">10161443</article-id><article-id pub-id-type="publisher-id">3264</article-id><article-id pub-id-type="doi">10.1186/s13287-023-03264-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Mesenchymal stromal cell-derived secretome-based therapy for neurodegenerative diseases: overview of clinical trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ghasemi</surname><given-names>Maryam</given-names></name><address><email>Maya.gh8@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Roshandel</surname><given-names>Elham</given-names></name><address><email>elham.roshandel@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mohammadian</surname><given-names>Mozhdeh</given-names></name><address><email>Mohammadian.hematology@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Farhadihosseinabadi</surname><given-names>Behrouz</given-names></name><address><email>Beh_far1364@yahoo.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Akbarzadehlaleh</surname><given-names>Parvin</given-names></name><address><email>Akbarzadehp@tbzmed.ac.ir</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8091-857X</contrib-id><name><surname>Shamsasenjan</surname><given-names>Karim</given-names></name><address><email>Shamsk@tbzmed.ac.ir</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution>Student Research Committee, Tabriz University of Medical Sciences, </institution></institution-wrap>Tabriz, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution>Stem Cell Research Center, </institution><institution>Tabriz University of Medical Sciences, </institution></institution-wrap>Tabriz, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Hematopoietic Stem Cell Research Center, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.412266.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1781 3962</institution-id><institution>Department of Hematology, School of Medicine, </institution><institution>Tarbiat Modares University (TMU), </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.417689.5</institution-id><institution>Breast Cancer Research Center, </institution><institution>Motamed Cancer Institute, ACECR, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.412888.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 8913</institution-id><institution>Pharmaceutical Biotechnology Department, Pharmacy Faculty, </institution><institution>Tabriz University of Medical Science, </institution></institution-wrap>Tabriz, Iran </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><elocation-id>122</elocation-id><history><date date-type="received"><day>19</day><month>6</month><year>2022</year></date><date date-type="accepted"><day>6</day><month>3</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Over the past few years, mesenchymal stromal cells (MSCs) have attracted a great deal of scientific attention owing to their promising results in the treatment of incurable diseases. However, there are several concerns about their possible side effects after direct cell transplantation, including host immune response, time-consuming cell culture procedures, and the dependence of cell quality on the donor, which limit the application of MSCs in clinical trials. On the other hand, it is well accepted that the beneficial effects of MSCs are mediated by secretome rather than cell replacement. MSC secretome refers to a variety of bioactive molecules involved in different biological processes, specifically neuro-regeneration.</p></sec><sec><title>Main body</title><p id="Par2">Due to the limited ability of the central nervous system to compensate for neuronal loss and relieve disease progress, mesenchymal stem cell products may be used as a potential cure for central nervous system disorders. In the present study, the therapeutic effects of MSC secretome were reviewed and discussed the possible mechanisms in the three most prevalent central nervous system disorders, namely Alzheimer's disease, multiple sclerosis, and Parkinson's disease. The current work aimed to help discover new medicine for the mentioned complications.</p></sec><sec><title>Conclusion</title><p id="Par3">The use of MSC-derived secretomes in the treatment of the mentioned diseases has encouraging results, so it can be considered as a treatment option for which no treatment has been introduced so far.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Mesenchymal stem cell</kwd><kwd>Secretome</kwd><kwd>Culture media</kwd><kwd>Exosomes</kwd><kwd>Neurodegenerative disorders</kwd><kwd>Cell-free therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par42">Neurodegenerative disorders can be the result of an injury to the brain and spinal cord neurons. When the body is unable to replace damaged neurons, structural damage and function failure lead to neuronal death. Consequently, dementia, mental dysfunction, and movement problems occur in neurodegenerative diseases, such as Parkinson&#x02019;s disease (PD) [<xref ref-type="bibr" rid="CR1">1</xref>], Alzheimer&#x02019;s disease (AD) [<xref ref-type="bibr" rid="CR2">2</xref>], and multiple sclerosis (MS) [<xref ref-type="bibr" rid="CR3">3</xref>]. Although the exact pathophysiology of neurodegenerative diseases is unclear, several studies have suggested that oxidative stress [<xref ref-type="bibr" rid="CR4">4</xref>], environmental pollution [<xref ref-type="bibr" rid="CR5">5</xref>], aging [<xref ref-type="bibr" rid="CR6">6</xref>], infection [<xref ref-type="bibr" rid="CR7">7</xref>], chemical exposure [<xref ref-type="bibr" rid="CR8">8</xref>], and immune dysregulation [<xref ref-type="bibr" rid="CR9">9</xref>] play a role in the accumulation of misfolded proteins (such as tau, amyloid-&#x003b2;, &#x003b1;-syncline) [<xref ref-type="bibr" rid="CR10">10</xref>] over time. Different types of pharmacotherapies were developed to treat more common neurodegenerative disorders, like AD [<xref ref-type="bibr" rid="CR11">11</xref>] and PD [<xref ref-type="bibr" rid="CR12">12</xref>]; among them, acetylcholinesterase inhibitors (donepezil and rivastigmine) and N-methyl-D-aspartate (NMDA) receptor agonists were found to be more effective, especially for AD [<xref ref-type="bibr" rid="CR13">13</xref>]. Regarding PD, only one drug, Xadago safinamide, has received FDA approval [<xref ref-type="bibr" rid="CR14">14</xref>]. Despite their ability to alleviate symptoms, these drugs cannot stop the disease progression [<xref ref-type="bibr" rid="CR15">15</xref>]. The available drugs for MS (glatiramer acetate, cladribine, natalizumab, mitoxantrone, and ocrelizumab) are ineffective in accelerating tissue repair [<xref ref-type="bibr" rid="CR16">16</xref>]; therefore, attempts have been made to find new effective therapeutic strategies, such as stem cell therapy, to treat neurodegenerative diseases [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par43">Mesenchymal stromal cells (MSCs) are cells with the capacity for self-renewal and differentiation into various cell lineages [<xref ref-type="bibr" rid="CR19">19</xref>]. The International Society of Cell Therapy (ISCT) states that MSCs must satisfy three criteria to be labeled as MSCs; these are adipogenesis, chondrogenesis, and osteogenesis; plastic adhesion property; and positivity of CD90, CD105, and CD73 surface markers along with negativity for CD45, CD19, CD79a, CD34, and human leukocyte antigen (HLA)-DR surface markers. In contrast to other stem cell groups, the expression of CD34 is believed to be challenging [<xref ref-type="bibr" rid="CR20">20</xref>], and no specific marker has been developed to identify MSCs [<xref ref-type="bibr" rid="CR21">21</xref>]. Mesenchymal stromal cells can be derived from several sources, including bone marrow, adipose tissue, dental tissues, placenta, umbilical cord blood, Wharton's jelly, and the brain [<xref ref-type="bibr" rid="CR22">22</xref>]. Despite meeting the abovementioned criteria, these mesenchymal stromal cells from different sources differ in several characteristics, such as their ability to differentiate into specific cell lineages, their cytokine secretion profiles, and surface markers [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par44">More than 2000 patients suffering from different stages of neurodegenerative diseases received MSCs, and most of them achieved promising results [<xref ref-type="bibr" rid="CR25">25</xref>]. Nonetheless, there are several concerns about MSC-based cell therapy, including heterogeneity, potential side effects after allogeneic MSC transplantation, and the difficulties in choosing proper donors. Heterogeneity could be due to differences in MSC sources and cell culture methods [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. This fact makes it difficult to compare results from clinical trials that have chosen different sources and methods. From another point of view, it can be considered a favorable option in applying MSC to treat different conditions by manipulating the culture medium and choosing the appropriate source to achieve the optimum results.</p><p id="Par45">Another concern is the host immune system's reaction after transplanting MSCs. The use of autogenic MSCs is considered an option to avoid this complication; however, it has certain limitations since the potential therapeutic effects of MSCs depend on the donor&#x02019;s age and health [<xref ref-type="bibr" rid="CR28">28</xref>]. Previous studies have revealed that MSCs obtained from patients with obesity [<xref ref-type="bibr" rid="CR29">29</xref>] and inflammatory diseases did not have normal differentiation and proliferation capacity; therefore, they could not produce the expected therapeutic effects [<xref ref-type="bibr" rid="CR30">30</xref>]. The last concern is about the growing data suggesting that MSC therapy may be ineffective, in particular for neural disorders. One reason may be the weak and transient benefit of MSC therapy in studies of central nerves system (CNS) disorders, such as ALS [<xref ref-type="bibr" rid="CR31">31</xref>], MS [<xref ref-type="bibr" rid="CR32">32</xref>], and stroke [<xref ref-type="bibr" rid="CR33">33</xref>]. It could be the result of an ineffective transplantation method. After intravenous (IV) transfusion, MSCs are trapped in some organs, mostly in the lungs [<xref ref-type="bibr" rid="CR34">34</xref>]. In most cases, they cannot cross the blood&#x02013;brain barrier successfully. Applying a novel method of MSCs transplantation, such as intralesional, intranasal, intra-arterial, or the use of MSC&#x02019;s secretome, solves this issue [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par46">The proteins released by cells are a straightforward definition of the secretome. Secretomes derived from MSCs include soluble (cytokines and chemokine) and insoluble (extra vesicles) factors [<xref ref-type="bibr" rid="CR36">36</xref>]. MSC-derived secretomes are composed of a protein-soluble fraction, like growth factors and cytokines, and a vesicular fraction, composed of microvesicles and exosomes. Insoluble components are released into the extracellular environment and participate in trafficking, adhesion, and endocrine signaling [<xref ref-type="bibr" rid="CR37">37</xref>]. Exosomes' cargo consists of three categories: I. proteins, which include signaling peptides, heat-shock proteins, vesicular transport proteins, signal transduction proteins, cytoskeletal proteins, and cell metabolism enzymes [<xref ref-type="bibr" rid="CR38">38</xref>]; II. lipids, which include ceramides, cholesterols, phosphatidylserines, and sphingomyelins; III. nucleic acids which include genomic DNA, mitochondrial DNA (mtDNA), transfer RNAs (tRNAs) [<xref ref-type="bibr" rid="CR39">39</xref>], messenger RNAs (mRNAs), ribosomal RNAs (rRNAs), complementary DNA (cDNAs), and small and long non-coding RNA [<xref ref-type="bibr" rid="CR40">40</xref>]. Numerous recent studies have highlighted the beneficial therapeutic effects associated with MSC transplantation to the CNS due to its higher paracrine activity than its cell differentiation capacity [<xref ref-type="bibr" rid="CR41">41</xref>]. The presence of immune regulatory and neurotrophic factors in MSCs&#x02019; secretome plays a crucial role in their desirable effects on CNS disorders. Some of these neurotrophic factors can increase neuronal proliferation and survival, such as nerve growth factor (NGF), glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4, vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), pigment epithelium-derived factor (PEDF), insulin-like growth factor (IGF)-1, IGF2, transforming growth factor-beta 1 (TGF-&#x003b2;1), interleukin (IL)-6, pigment epithelium-derived factor (PEDF), DJ-1, and cystatin-C (Cys-C) [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par47">To obtain MSC-derived exosomes, first, MSCs cultivated in an exosome production medium, and then the supernatant undergoes the isolation methods. The lack of standard isolation and purification methods is the main obstacle in routing exosomes into the translational clinical application. Although exosome isolation is conventionally performed using ultracentrifugation (differential ultracentrifugation, density gradient centrifugation), the gold-standard method, other techniques have been developed to overcome the ultracentrifugation limitations. The alternative isolation techniques are based on isolation by size (ultrafiltration, sequential filtration, exosome isolation kits, size exclusion chromatography, flow field-flow fractionation, hydrostatic filtration dialysis), immunoaffinity capture (enzyme-linked immunosorbent assay, magneto-immunoprecipitation), exosome precipitation (polyethylene glycol precipitation, lectin induced agglutination), and microfluidic techniques (acoustic nano-filter, immuno-based microfluidic isolation). Each isolation method has some advantages and disadvantages. For instance, immunoprecipitation yields the most efficient recovery rate, while the acoustic nano-filter method gives the highest purity and requires the least sample volume and time. The exosome analysis is performed via different methods based on physical characteristics (electron microscopy, dynamic light scattering, nanoparticle tracking analysis, tunable resistive pulse sensing), chemical, biochemical, and compositional characteristics (immunodetection methods such as flow cytometry and western blotting, thermophoretic profiling, and mass spectrometry-based proteomic analysis) [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par48">In this study, the effects of MSCs on cells on CNS injury were reviewed. The focus of the study was on secretome in three common diseases, namely Alzheimer&#x02019;s disease, Parkinson&#x02019;s disease, and MS. This was done to explore the therapeutic horizons concerning these conditions.</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>Mechanism of function</title><p id="Par49">Different mechanisms are considered to explain the beneficial effects of MSC transplantation [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In vivo studies have shown that autologous or exogenous MSCs could modify tissue structure and function by migrating to damaged areas, which involves several steps. Although the exact homing mechanism is not fully understood, there is a hypothesis based on its similarity to leukocyte migration via integrins, selectins, adhesion molecules (like VCAM-1), and G-protein signaling pathways [<xref ref-type="bibr" rid="CR46">46</xref>]. Upon migration to the CNS, MSCs interact with surrounding tissues. This leads to neuronal differentiation and secretion of cytokines and growth factors involved in various mechanisms, such as neuroprotection, immunoregulation, angiogenesis, and inhibiting neuronal apoptosis [<xref ref-type="bibr" rid="CR47">47</xref>]. Despite the beneficial features of MSCs, they show limited differentiation capacity compared to other types of stem cells, like embryonic pluripotent stem cells. It is not entirely accepted that MSCs can replace all lost neurons through neural differentiation. Therefore, improvement in neuronal survival following MSC administration is possibly due to the secretion of various neurotrophic factors by MSCs rather than differentiation. Secretion of neurotrophic factors can be increased by manipulating culture media [<xref ref-type="bibr" rid="CR48">48</xref>]. Some priming protocols have been assessed in MSC culture media to induce particular alterations, leading to desirable changes [<xref ref-type="bibr" rid="CR49">49</xref>]. For instance, Redondo-Castro et al. reported that preconditioning treatments of MSCs with inflammatory cytokines, like IL-1, prime them for a neurotrophic phenotype to release secretomes containing neurotrophic and anti-inflammatory cargos in the culture media supernatant []. Findings indicated that inducing MSCs to overexpress neurotrophic factors like GDNF and BDNF resulted in promising outcomes in PD and AD mouse models [<xref ref-type="bibr" rid="CR50">50</xref>]. Moreover, using dynamic culturing conditions in computer-controlled bioreactors induces MSCs to produce a higher amount of neurotrophic factor, leading to a more effective cocktail for therapeutic applications in neurodegenerative disease [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par50">Immune dysfunctionality has been introduced as one of the main causes of neurodegenerative diseases such as AD, PD, and MS. In this light, glial cells&#x02019; hyperactivity and immune cells&#x02019; infiltration into the CNS lead to disease progression [<xref ref-type="bibr" rid="CR3">3</xref>]. But the MSCs&#x02019; capacity to affect the proliferation and activation of all types of immune cells is another promising feature that assures their efficacy in neurodegenerative disorders [<xref ref-type="bibr" rid="CR53">53</xref>]. MSCs are not immunosuppressive by nature, but they need a specific cytokine profile [<xref ref-type="bibr" rid="CR54">54</xref>]. However, the exact mechanism is still under question. Some reports have indicated that it occurs directly through cell-cell contact and secreting soluble factors [<xref ref-type="bibr" rid="CR55">55</xref>]. MSCs interrupt three pivotal phases of the immune response: antigen presentation, T cell activation and proliferation, and effectors&#x02019; responses [<xref ref-type="bibr" rid="CR53">53</xref>], through modulating the behavior of macrophages, dendritic cells (DCs), natural killer cells (NK cells), B cells, and T cells. It happens mostly through secreting certain molecules, including indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), TGF-&#x003b2;1, HLA-G5, IL-10, and IL-6 [<xref ref-type="bibr" rid="CR56">56</xref>]. Besides, the mediators secreted by MSCs comprise various cytokines and growth factors that mostly play an immunomodulatory role in the cell microenvironment. They also actively produce neurotrophic factors like BDNF, GDNF, VEGF, NT-3, NGF, and IGF, which induce endogenous neurogenesis and raise neuronal survival. Numerous studies have confirmed the neuro-protective effects of these growth factors [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. GDNF, as a well-known trophic factor, was reported to exhibit remarkable neuroprotective properties [<xref ref-type="bibr" rid="CR59">59</xref>]. BDNF is the main promoting agent to axonal outgrowth in the CNS, since with its removal from the secretome, the effect was not observed anymore [<xref ref-type="bibr" rid="CR60">60</xref>]. Moreover, several papers have introduced VEGF as another critical factor, which induces explicitly axonal outgrowth [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. This result was confirmed by Zhou et al. as they promoted neurogenesis and functional recovery following VEGF and BDNF co-overexpressed MSC administration to the cerebral ischemia model [<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par51">MSCs can impair antigen presentation by DCs through reducing surface markers such as CD-11c, major histocompatibility complex (MHC)-class II, and CD83, indirectly leading to the inhibition of adaptive immune cell activation [<xref ref-type="bibr" rid="CR64">64</xref>]. Cross-talk with macrophages, which play an imperative role in CNS inflammation under the high level of inflammatory cytokines (IFN-&#x003b3; and TNF-&#x003b1;), polarizes them toward anti-inflammatory phenotype (M2), unlike pro-inflammatory (M1), which can contribute to tissue regeneration by increasing arginase-1 and IL-10 levels [<xref ref-type="bibr" rid="CR65">65</xref>]. Microglial cells, which are resident macrophages in CNS tissue, can cause inflammation (by secreting IL-6, NO, TNF-&#x003b1;, and IL-1&#x003b2;) and are related to different pathogens of neurodegenerative disorders [<xref ref-type="bibr" rid="CR66">66</xref>]. MSCs, through secretion of TNF-&#x003b1;, stimulated protein 6 (TSG-6), suppress microglia activation [<xref ref-type="bibr" rid="CR67">67</xref>], and exert M1 to M2 switch by activating the CX3CL1/CX3CR1 signaling pathway in these cells [<xref ref-type="bibr" rid="CR68">68</xref>].</p><p id="Par52">MSCs suppress lymphocytes via three vital mechanisms: firstly, reducing the proliferation of both T [<xref ref-type="bibr" rid="CR69">69</xref>] and B [<xref ref-type="bibr" rid="CR70">70</xref>] lymphocytes by arresting the cell cycle in the G0/G1 phase even after exposure to allogenic cells; secondly, reducing IFN-&#x003b3; and IL-17 production by polarizing the Th0 toward Th2 shift rather than that toward Th1 and Th17; and lastly, indirect induction of Treg generation [<xref ref-type="bibr" rid="CR71">71</xref>]. It has been shown that MSCs exert further Treg immune suppression activity, probably via IL-10 secretion [<xref ref-type="bibr" rid="CR72">72</xref>]. It could be a reassuring option for treating CNS disorders with autoimmune origins, such as MS.</p><p id="Par53">Other secretory products, like HLA-G5, TGF-&#x003b2;1, IDO, and PGE2, suppress the proliferation, cytokine secretion, and cytotoxicity of NK cells. They also inhibit the activity of NK cells as a bridge between innate and adaptive immune responses [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par54">To sum up, the beneficial effect of MSCs on neurodegenerative disorders is mostly attributed to the secretion of several cytokines and growth factors involved in immune regulation and neuroprotection.</p></sec><sec id="Sec4"><title>Secretome-based therapy in neurodegenerative diseases</title><p id="Par55">Gnocchi first discovered the therapy based on MSC secretome in 2005 [<xref ref-type="bibr" rid="CR44">44</xref>], which attracted scientific attention owing to addressing several concerns about the side effects following allogenic or autologous MSC transplantation. In addition to the risk of immune response and tumor genesis, culturing MSCs takes too much time for cell proliferation and may be associated with undesirable differentiation [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. On the other hand, MSC secretomes can be easily collected from commercial culture media without any invasive process [<xref ref-type="bibr" rid="CR75">75</xref>]. Furthermore, in various types of diseases related to the damaged structure of different brain parts, administering culture media is effective. These reasons, along with the high prevalence of central nervous system disorders and their low regenerative potential, make these diseases one of the critical targets for MSC secretome-based therapy. Numerous studies have verified the neuroprotective and neurotrophic effects of MSC secretome based on this hypothesis [<xref ref-type="bibr" rid="CR76">76</xref>]. Teixeira et al. reported that just a single administration of MSC secretome, even without cell transplantation, increased endogenous neuronal differentiation in the hippocampus region [<xref ref-type="bibr" rid="CR77">77</xref>]. MSC-derived secretomes are flexible according to the state and site of the injury [<xref ref-type="bibr" rid="CR78">78</xref>]. Therefore, they could be regulated by various pathological conditions similar to what may be observed in different CNS disorders.</p><p id="Par56">In the following sections, the studies conducted on the effect of secretome-based therapies in the three main neurodegenerative diseases, including AD, PD, and MS, are reviewed (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Therapeutic effects of MSC in animal models of neurodegenerative diseases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Disease</th><th align="left">Tissue source of MSC</th><th align="left">Therapeutic effects</th><th align="left">Refs.</th><th align="left">Year</th></tr></thead><tbody><tr><td align="left" rowspan="15">AD</td><td align="left">Rat AD</td><td align="left">Reduced oxidative stress; alleviated cognitive impairment; promoted neurogenesis; increased the neuroblasts numbers</td><td align="left">[<xref ref-type="bibr" rid="CR152">152</xref>]</td><td align="left">2014</td></tr><tr><td align="left">Human UCB</td><td align="left">Improved endogenous hippocampal neurogenesis and synaptic activity</td><td align="left">[<xref ref-type="bibr" rid="CR153">153</xref>]</td><td align="left">2015</td></tr><tr><td align="left">Human WJ</td><td align="left">Improved the spatial learning; mitigated memory decline; reduced A&#x003b2; soluble levels and its deposition</td><td align="left">[<xref ref-type="bibr" rid="CR154">154</xref>]</td><td align="left">2016</td></tr><tr><td align="left">Human WJ and UCB</td><td align="left">Induced neuronal development and neurite outgrowth</td><td align="left">[<xref ref-type="bibr" rid="CR155">155</xref>]</td><td align="left">2016</td></tr><tr><td align="left">Human WJ</td><td align="left">Reduces the accumulation of ubiquitin-conjugated proteins</td><td align="left">[<xref ref-type="bibr" rid="CR156">156</xref></td><td align="left">2017</td></tr><tr><td align="left">Human AM</td><td align="left">Reduced amyloid-&#x003b2; peptide deposition; rescued spatial learning and memory</td><td align="left">[<xref ref-type="bibr" rid="CR157">157</xref>]</td><td align="left">2017</td></tr><tr><td align="left">Mouse BM</td><td align="left">Reduced A&#x003b2; plaque size</td><td align="left">[<xref ref-type="bibr" rid="CR158">158</xref>]</td><td align="left">2017</td></tr><tr><td align="left">Human UCB</td><td align="left">Mitigated A&#x003b2;-induced synaptic dysfunction</td><td align="left">[<xref ref-type="bibr" rid="CR159">159</xref>]</td><td align="left">2018</td></tr><tr><td align="left">Human MenSCs</td><td align="left">Improved spatial learning and memory; mitigated amyloid plaques; increased A&#x003b2; degrading enzymes; modulated panel of proinflammatory cytokines</td><td align="left">[<xref ref-type="bibr" rid="CR160">160</xref>]</td><td align="left">2018</td></tr><tr><td align="left">Mouse BM</td><td align="left">Improved cognitive impairment</td><td align="left">[<xref ref-type="bibr" rid="CR161">161</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Mouse BM</td><td align="left">Reduction &#x003b2;-amyloid deposits</td><td align="left">[<xref ref-type="bibr" rid="CR162">162</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Human UCB</td><td align="left">Improved the spatial learning; improved memory impairment</td><td align="left">[<xref ref-type="bibr" rid="CR163">163</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Rat BM</td><td align="left">Improved cognitive impairment</td><td align="left">[<xref ref-type="bibr" rid="CR164">164</xref> ]</td><td align="left">2020</td></tr><tr><td align="left">Mouse BM</td><td align="left">Memory recovery; reduced neuro-inflammation; decreased brain amyloidosis; increased neuronal density in cortex and hippocampus; diminished hippocampal shrinkage</td><td align="left">[<xref ref-type="bibr" rid="CR165">165</xref>]</td><td align="left">2021</td></tr><tr><td align="left">Human WJ</td><td align="left">Reduced cell death; reduced ubiquitin conjugate levels; reduced A&#x003b2; levels</td><td align="left">[<xref ref-type="bibr" rid="CR166">166</xref>]</td><td align="left">2021</td></tr><tr><td align="left" rowspan="14">MS</td><td align="left">Mouse BM</td><td align="left">Improved clinical score</td><td align="left">[<xref ref-type="bibr" rid="CR167">167</xref>]</td><td align="left">2015</td></tr><tr><td align="left">Mouse BM</td><td align="left">Decreased T helper-17 activation and function</td><td align="left">[<xref ref-type="bibr" rid="CR168">168</xref>]</td><td align="left">2015</td></tr><tr><td align="left">Mouse BM</td><td align="left">Increased remyelination; decreased demyelination and apoptosis</td><td align="left">[<xref ref-type="bibr" rid="CR169">169</xref>]</td><td align="left">2015</td></tr><tr><td align="left">Mouse AD</td><td align="left">Reduced disease severity, inflammatory cell infiltration, and demyelination</td><td align="left">[<xref ref-type="bibr" rid="CR170">170</xref>]</td><td align="left">2017</td></tr><tr><td align="left">Rat BM</td><td align="left">Increased clinical score; declined inflammation</td><td align="left">[<xref ref-type="bibr" rid="CR171">171</xref>]</td><td align="left">2017</td></tr><tr><td align="left">Mouse BM</td><td align="left">Decreased vascular alteration of vessels, myelin, and neuronal damage</td><td align="left">[<xref ref-type="bibr" rid="CR172">172</xref>]</td><td align="left">2017</td></tr><tr><td align="left">Human BM</td><td align="left">Diminished demyelination in corpus callosum</td><td align="left">[<xref ref-type="bibr" rid="CR173">173</xref>]</td><td align="left">2018</td></tr><tr><td align="left">Mouse BM</td><td align="left">Improved therapeutic function</td><td align="left">[<xref ref-type="bibr" rid="CR174">174</xref>]</td><td align="left">2018</td></tr><tr><td align="left">Rat BM</td><td align="left">Differentiation of oligodendrocyte precursor cells</td><td align="left">[<xref ref-type="bibr" rid="CR175">175</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Mouse BM</td><td align="left">Improved remyelination; declined microgliosis and astrocytosis</td><td align="left">[177]</td><td align="left">2019</td></tr><tr><td align="left">Mouse BM</td><td align="left">Increased M2 phenotype macrophage; decreased M1 phenotype macrophage</td><td align="left">[<xref ref-type="bibr" rid="CR177">177</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Mouse BM</td><td align="left">Reduced inflammatory infiltration and demyelination of spinal cord</td><td align="left">[<xref ref-type="bibr" rid="CR178">178</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Mouse BM</td><td align="left">Increased neurobehavioral outcomes; reduced blood&#x02013;brain barrier disruption, inflammatory infiltration, and demyelination in spinal cord</td><td align="left">[<xref ref-type="bibr" rid="CR179">179</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Human BM</td><td align="left">Increased retinal ganglion cell function and motor sensory impairment</td><td align="left">[<xref ref-type="bibr" rid="CR180">180</xref>]</td><td align="left">2020</td></tr><tr><td align="left" rowspan="14">PD</td><td align="left">Rat BM</td><td align="left">Neuro-protective effects on dopaminergic neurons</td><td align="left">[<xref ref-type="bibr" rid="CR181">181</xref>]</td><td align="left">2008</td></tr><tr><td align="left">Rat BM</td><td align="left">Partial rescue of dopaminergic pathway</td><td align="left">[<xref ref-type="bibr" rid="CR182">182</xref>]</td><td align="left">2008</td></tr><tr><td align="left">Mouse BM</td><td align="left">Neuro-protective effects on dopaminergic neurons; reduced blood&#x02013;brain barrier damage; downregulation of neuro-inflammation</td><td align="left">[<xref ref-type="bibr" rid="CR183">183</xref>]</td><td align="left">2009</td></tr><tr><td align="left">Rat BM</td><td align="left">Improved viability of striatal/nigral dopaminergic terminals concomitant</td><td align="left">[<xref ref-type="bibr" rid="CR184">184</xref>]</td><td align="left">2010</td></tr><tr><td align="left">Human endometrial</td><td align="left">Improved dopamine production</td><td align="left">[<xref ref-type="bibr" rid="CR185">185</xref>]</td><td align="left">2011</td></tr><tr><td align="left">Human BM</td><td align="left">No effect on motor impairment</td><td align="left">[<xref ref-type="bibr" rid="CR186">186</xref>]</td><td align="left">2015</td></tr><tr><td align="left">Human endometrial</td><td align="left">Enhanced dopamine metabolite concentrations</td><td align="left">[<xref ref-type="bibr" rid="CR187">187</xref>]</td><td align="left">2015</td></tr><tr><td align="left">Rat BM</td><td align="left">Restored rotational behavior</td><td align="left">[<xref ref-type="bibr" rid="CR188">188</xref>]</td><td align="left">2015</td></tr><tr><td align="left">Rat BM</td><td align="left">Improved locomotor functions</td><td align="left">[<xref ref-type="bibr" rid="CR189">189</xref>]</td><td align="left">2017</td></tr><tr><td align="left">Rat BM</td><td align="left">Differentiation into nestin- and neuron-specific enolase-positive cells</td><td align="left">[<xref ref-type="bibr" rid="CR190">190</xref>]</td><td align="left">2017</td></tr><tr><td align="left">Human BM</td><td align="left">Reduced pro-inflammatory cytokines; restored behavioral function</td><td align="left">[<xref ref-type="bibr" rid="CR191">191</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Human BM</td><td align="left">Down-regulated pro-inflammatory cytokines; stimulated antioxidant enzymes</td><td align="left">[<xref ref-type="bibr" rid="CR193">193</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Human AT</td><td align="left">Induced alteration in dopamine transporter expression; promoted neurotrophic factors</td><td align="left">[<xref ref-type="bibr" rid="CR192">192</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Human WJ</td><td align="left">Restored dopaminergic neurons; enhanced levels of neurotrophic factors</td><td align="left">[<xref ref-type="bibr" rid="CR194">194</xref>]</td><td align="left">2020</td></tr></tbody></table><table-wrap-foot><p><italic>AD</italic> Alzheimer&#x02019;s disease, <italic>MS</italic> Multiple sclerosis, <italic>PD</italic> Parkinson&#x02019;s disease, <italic>BM-MSCs</italic> Bone marrow-derived mesenchymal stem cells, <italic>WJ-MSCs</italic> Wharton&#x02019;s Jelly mesenchymal stem cells, <italic>UCB-MSCs</italic> Umbilical cord blood-derived mesenchymal stem cells, <italic>MenSCs</italic> Menstrual blood-derived mesenchymal stem cells, <italic>AD-MSCs</italic> Adipose tissue-derived mesenchymal stem cells, <italic>AM-MSCs</italic> Amniotic mesenchymal stem cells</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Alzheimer's disease (AD)</title><p id="Par57">AD is a prevalent chronic disease of the central nervous system with multifactorial and relatively complex pathology. AD patients suffer from the gradual loss of brain abilities such as memory and cognitive function. It has been estimated that approximately 131 million people, even those under the age of 65, will be affected until 2050 worldwide.</p><p id="Par58">AD was primarily discovered in 1907 by Alzheimer, a neuropathologist specialist [<xref ref-type="bibr" rid="CR79">79</xref>], and has since been divided into sporadic (sAD) and familial (fAD) groups. In the fAD group, three common gene mutations were reported, namely presenilin 1 (PSEN1), presenilin 2 (PSEN2) &#x003b2;, and precursor protein (APP) [<xref ref-type="bibr" rid="CR80">80</xref>]. In sAD, apolipoprotein E (APOE), nutrition, lifestyle, and aging are known as major risk factors. However, the exact underlying mechanism remains ambiguous. Any efficient drug or curative method has been investigated. Although some current treatment methods, including cholinesterase blockers and NMDA receptor antagonists, are effective in the early stages of the disease, they are not highly efficient after a while due to a high number of neuronal losses in the hippocampus, the inability of drugs to cross the blood&#x02013;brain barrier (BBB), and the increasing side effects following long-term use [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par59">The main pathological features in both fAD and sAD are chronic accumulation of amyloid-beta (A&#x003b2;) plaque and neurofibrillary tangles (NFT) enriched by hyperphosphorylated protein tau [<xref ref-type="bibr" rid="CR74">74</xref>]. This accumulation leads to the hyperactivation of microglia (MG) and astrocytes (AC) as the most involved immune cells in AD pathology [<xref ref-type="bibr" rid="CR82">82</xref>]. Brain neurons of AD patients are permanently susceptible to inflammatory conditions induced by these immune cells. Although opinions about the role of MG and AC are controversial, most researchers consider them immunostimulators after exposure to A&#x003b2; plaques by their toll-like surface receptors (TLRs) (TLR 2, TLR4, TLR6, and TLR9) and CD markers (CD36, CD14, and CD47) [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Expression of these TLRs in different cells has been suggested as the initiation of the inflammatory response. Thus, increased TLR2 levels are considered a diagnostic marker for activated MGs [<xref ref-type="bibr" rid="CR85">85</xref>], and TLR4 overexpressing neurons are more prone to degradation after releasing IL-1B, TNF&#x003b1;, and IL-17 [<xref ref-type="bibr" rid="CR86">86</xref>]. Modulating the TLRs' stimulation would be a critical step to control MG activation and AC status. In this context, one paper showed that hypoxia-preconditioned adipocyte-derived MSC secretome injection to AD mouse models decreased TLR2 and TLR4 expression, similar to astrocyte inflammatory cytokines, such as IL-1 and TNF&#x003b1;, which increase hippocampus neuronal survival [<xref ref-type="bibr" rid="CR87">87</xref>].</p><p id="Par60">Secreting inflammatory cytokines by activated MGs and ACs plays an important role in disease progression, neurotoxicity, and cognitive dysfunction [<xref ref-type="bibr" rid="CR88">88</xref>]. Using IL-17 neutralizing antibodies improved memory function in an animal model of AD by preventing pro-inflammatory mediators [<xref ref-type="bibr" rid="CR89">89</xref>]. On the other hand, some types of secretory products are crucial factors that cause resistance to the accumulation of AB plaque in the brain. An interesting study examined the expression of inflammatory and anti-inflammatory cytokines in the brains of the resistance group. Comparing the control and AD groups showed that they expressed different cytokines, which prevented neurodegeneration and dementia despite the presence of AB plaque [<xref ref-type="bibr" rid="CR90">90</xref>]. The resistance groups differed in the number of A&#x003b2; plaques and NTFs. Higher levels of IL-6, IL-1ra, IL-13, and IL-4 belonged to the highest rate group (HP), whereas the dominant cytokines in the lowest rate group (LP) were IL-10, IL-6, and IP10. Among them, IL-4, IL-13, and IL-10 shifted the activated MG to M2 form to modulate the inflammatory response. The M1 phenotype massively releases inflammatory cytokines, which deteriorate CNS damage [<xref ref-type="bibr" rid="CR91">91</xref>]. Conversely, the phenotypical exchange of glial cells in AD has been reported in favor of the inflammatory process. This has been reported during aging, diabetes, obesity, and some other mentioned risk factors associated with immune disturbances [<xref ref-type="bibr" rid="CR92">92</xref>].</p><p id="Par61">The MSC secretome comprises an array of bioactive molecules that ameliorate AD-related symptoms through different mechanisms (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Graphical summary of different mechanisms conducted by MSCs secretome to hippocampal neuron protection. MSC products ameliorate neurodegeneration related to (A1) astrocyte and (M1) microglia, two major immune cells involved in the pathogenesis of Alzheimer&#x02019;s disease. CX3CL1, IL- 4, IL-13, and IL-10 induced MGs switching from harmful phenotype M1 to protective form M2. Exosomes decrease the expression levels of IL-1a, IL-1&#x003b2;, and TNF-&#x003b1;; thus, MSCs can modulate the excessive inflammatory responses. The elevated secretion of CCL5 and ICAM-1 induces A&#x003b2; plaque degradation by increasing the level of protease enzyme (NEP). VEGF and FGF-2 can decrease neuronal apoptosis by changing the BAX/BCL-2 balance in favor of cell survival. IL: interleukin, TGF-&#x003b2;: transforming growth factor-beta, Fractalkine R: fractalkine receptor, TLR: Toll-like receptor, NEP: neprilysin, A&#x003b2;: amyloid beta, BAX: BCL-2-associated X, apoptosis regulator, BCL-2: B cell CLL/lymphoma 2. The images depicted in the figure are designed by authors</p></caption><graphic xlink:href="13287_2023_3264_Fig1_HTML" id="MO1"/></fig></p><p id="Par62">Transplantation of hypoxia-preconditioned MSC-exosomes to app/PS1 mouse models induced phenotypic exchanges in the lesion area by decreasing the expression levels of IL-1a, IL-1&#x003b2;, and TNF-&#x003b1; and increasing IL-4 and IL-10; thus, MSCs can modulate the excessive inflammatory responses caused by M1 MGs. Additionally, they suppressed the activation of astrocytes and decreased AB plaque deposition, leading to improved memory deficits and cognitive AD-related disorders [<xref ref-type="bibr" rid="CR88">88</xref>]. In line with previous studies, MSC-derived CX3CL1 induced MGs switch from harmful phenotype M1 to protective form M2 through the fractalkine receptor, thereby protecting neurons against destructive effects following inflammatory cytokines release [<xref ref-type="bibr" rid="CR93">93</xref>].</p><p id="Par63">A high concentration of inflammatory products is commonly believed a sign of MGs and ACs shifting to a harmful form that compromises A&#x003b2; clearance. However, it seems that it could not be applied to all inflammatory cytokines [<xref ref-type="bibr" rid="CR94">94</xref>]. Multiple studies have found TGF-&#x003b2;, IL-6, and other inflammatory cytokines accumulating around A&#x003b2; plaques in the brains of AD patients [<xref rid="Fig2" ref-type="fig">2</xref>]. According to researchers, these two cytokines protect neurons by increasing plaque clearance, which results in improved cognitive and behavioral disorders [<xref ref-type="bibr" rid="CR29">29</xref>]. IL-6, a pleiotropic cytokine expressed at a high rate in both resistance groups (HP and IP), was reported to be protective and increase neuronal survival. Contrary to normal conditions, IL-6 concentration was shown to be significantly increased during disease progression [<xref ref-type="bibr" rid="CR95">95</xref>]. However, data in this context are controversial since IL-6, as a well-known inflammatory mediator, might either initiate a harmful cascade leading to cerebral damage or facilitate the healing process via raising angiogenesis and other protective mechanisms [<xref ref-type="bibr" rid="CR96">96</xref>]. In this regard, Yang et al. indicated reduced autophagy in hippocampal neurons induced by endogenous MSC-derived IL-6 by inhibiting the AMPK/mTOR pathway via the gp130-IL-6R receptor complex. They revealed that MSC-derived IL-6 significantly decreases Beclin 1 and LC3 II, autophagy-associated proteins (Fig.&#x000a0;<xref ref-type="bibr" rid="CR97">97</xref>) [<xref ref-type="bibr" rid="CR98">98</xref>]. It was also reported that this cytokine could decrease the proliferation of activated astrocytes by affecting the AMPK/mTOR signaling pathway [<xref ref-type="bibr" rid="CR99">99</xref>]. Further investigation is needed to clarify the reciprocal role of inflammatory cytokines in AD.<fig id="Fig2"><label>Fig. 2</label><caption><p>MSC-derived IL-6 suppresses the autophagy pathway in injured hippocampal neurons in Alzheimer&#x02019;s disease through the downregulation of the AMPK (mitogen-activated protein kinase) signaling pathway. The AMPK signaling pathway is a downstream target of IL-6. IL-6 binds to the gp130-IL-6R receptor complex and induces a downregulation in the AMPK signaling pathway. IL-6 can induce mTOR, a pivotal factor in the autophagic signaling pathway, in an AMPK-dependent and STAT3-independent manner, leading to decreasing autophagy-associated proteins like Beclin 1 and LC3 II. The images depicted in the figure are designed by authors</p></caption><graphic xlink:href="13287_2023_3264_Fig2_HTML" id="MO2"/></fig></p><p id="Par64">Lee et al. injected bone marrow (BM)-derived MSCs into the hippocampal region of AD mice and realized that BM-derived MSCs could recruit activated MG cells to the inflamed area after exposure to A&#x003b2; deposition. The elevated secretion of CCL5, a chemoattractant factor, induced the recruitment of alternatively activated MG. Alternatively activated MGs attenuated memory impairment and decreased A&#x003b2; plaques through the secretion of IL-4 and neprilysin (NEP) [<xref ref-type="bibr" rid="CR100">100</xref>]. Several beneficial effects of IL-4 were previously reported in AD, including improved spatial learning and increased A&#x003b2; degradation in phagocytic cells [<xref ref-type="bibr" rid="CR101">101</xref>].</p><p id="Par65">MSCs secretome can indirectly contribute to A&#x003b2; plaque degradation through the NEP enzyme. Neprilysin is a well-known protease enzyme that has an inverse relationship with the A&#x003b2; level. Recently, it has become a new target in the search for novel AD therapies. Cultured MSC-derived secretomes have the potential to regulate neprilysin&#x02019;s activity. In vitro studies have revealed that MSC-derived soluble intracellular adhesion molecule-1 (ICAM-1) [<xref ref-type="bibr" rid="CR99">99</xref>] and CCL5 [<xref ref-type="bibr" rid="CR100">100</xref>] induce A&#x003b2; plaque degradation by increasing the level of NEP through alternative activation of MG cells. However, there is little knowledge about this enzyme and it needs further investigation.</p><p id="Par66">MSC secretome not only contains NEP, but can also decrease the toxic effects and neuronal apoptosis caused by A&#x003b2;. MSC-derived secretome significantly reduced neuronal apoptosis by changing the BAX/BCL-2 balance in favor of cell survival. A&#x003b2; plaques induce neuronal apoptosis either directly by upregulating the Bax protein [<xref ref-type="bibr" rid="CR102">102</xref>] or indirectly through increasing ROS-induced oxidative stress [<xref ref-type="bibr" rid="CR103">103</xref>]. Dental pulp stem cell (DPSC)-derived secretomes can counteract Bax expression in neuroblastoma cell lines through upregulation of the anti-apoptotic protein Bcl-2. Scientists believed that it could be related to the expression of RANTES, Fractalkine, VEGF, and fibroblast growth factor-2 (FGF-2), which can promote Bcl-2 expression. Interestingly, it has also been proven that DPSCs secrete these cytokines and growth factors at higher concentrations than other common sources of MSC, like bone marrow and adipocytes [<xref ref-type="bibr" rid="CR76">76</xref>]. Based on the aforementioned data, manipulating some factors aiming to upregulate Bcl-2 expression would be a promising strategy to develop more efficient therapies.</p><p id="Par67">In summary, AD neuropathology is a relatively complex disease and requires multi-target therapy approaches. The use of MSCs with neuroprotection potential, potent immune modulation, and anti-amyloidogenic activities could be considered a multi-approach alternative for AD model therapy. MSC secretome immunomodulatory properties are partially regulated by MG and AC activity, either by regulating their proliferation potential and phenotypic changes from neurodegenerative to neuroprotective states, or by regulating TLR expression. However, further clinical trials are required to explain which one is precisely responsible for the observed therapeutic outcomes and optimize this option.</p></sec><sec id="Sec6"><title>Multiple sclerosis (MS)</title><p id="Par68">MS is one of the prevalent neurodegenerative disorders affecting approximately 2.5 million people aged 20&#x02013;40&#x000a0;years [<xref ref-type="bibr" rid="CR103">103</xref>]. It is caused by the immune system attack through T helper reactive cells (TCD4&#x02009;+) and antibodies against the lipoprotein of nerve fibers, due to genetic and environmental backgrounds. Chronic degeneration of myelin sheath leads to a progressive disability in patients. MS is divided into three stages according to clinical symptoms [<xref ref-type="bibr" rid="CR104">104</xref>]. The most common type is relapse-remitting (RR) MS which occurs at an approximate rate of 85%-90% and is characterized by exacerbation and relative remission cycles [<xref ref-type="bibr" rid="CR105">105</xref>]. The second phase is defined as "secondary progressive" (SP) and characterized by aggravated symptoms without remission periods, affecting 50&#x02013;60% of MS patients. The third phase is defined as "primary progressive" (PP) and presented in about 15% of MS patients and is characterized by more severe clinical symptoms and chronic progressive disability with or without exacerbation episodes. Both SP and RR are more severe and frequent in women than in men [<xref ref-type="bibr" rid="CR106">106</xref>].</p><p id="Par69">Injury of the blood&#x02013;brain barrier followed by infiltration of immune cells into the brain and spinal cord occurs in the early stages of MS [<xref ref-type="bibr" rid="CR107">107</xref>]. Nevertheless, the exact reason behind the immune reaction against the nerve fibers remains unclear to date. The major pathological cause is a disturbance of the balance between T cell populations (TCD4&#x02009;+&#x02009;and Treg) and antigen-presenting cells (microglia) in favor of inflammation following neuronal degeneration. The major subset of autoreactive CD4&#x02009;+&#x02009;cells (Th1, Th17) seems to be critically involved in MS pathogenesis and its experimental animal model, experimental autoimmune encephalomyelitis (EAE) [<xref ref-type="bibr" rid="CR108">108</xref>]. Hence, transferring Th<sub>17</sub>/Th<sub>17</sub> cells to healthy rats causes EAE. Th1 and Th17 negatively affect immune tolerance, leading to inflammatory damage in MS, Th17 by producing inflammatory cytokines such as IL-17a, IL-17F, IL-21, IL-22, and Th1 by secreting TNF-&#x003b1; and IFN-&#x003b3; [<xref ref-type="bibr" rid="CR109">109</xref>]. Thus, these cytokines are abundantly expressed in the inflammation area. Although the healing process of neurons occurs naturally, it is not enough to compensate for neuronal loss and prevent disease progression. The current treatment methods (anti-inflammatory drugs, antioxidants, steroidal hormones, and corticosteroids) are available only for RR patients and reduce the number of relapses through immune system suppression [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. Nonetheless, they cannot stop degradation and replace lost neurons. Moreover, in the case of using this kind of therapies the potential side effects, such as secondary autoimmune disease and increased risk of infection, should be seriously considered [<xref ref-type="bibr" rid="CR111">111</xref>].</p><p id="Par70">As mentioned previously, the role of immune cells is undeniable in MS pathogenesis. Accordingly, targeting these immune cells and recovering from immune hemostasis can be an effective and promising strategy for treating this disease. MSC-derived secretome can justify the unbalanced immune response in MS through different mechanisms. These factors also exhibit neuroprotective effects that inhibit neuronal degeneration after the disease's progression. The following paragraphs describe different mechanisms induced by MSC secretome (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Graphical summary of immunomodulation and neuroprotective effects of MSCs in MS. MSC-derived secretome justifies the unbalanced immune response through secretion of different cytokines and growth factors. These products inhibit the proliferation, differentiation, and migration of Th1 and Th17 to the CNS and increase the Th0 differentiation to Treg instead. MSC secretome also comprises an array of neurotrophic factors which induce endogenous neurogenesis; this compensates lost neurons. MMP9: matrix metalloproteinases9, TIMP: tissue inhibitor of metalloproteinase, IL: interleukin, IFN-&#x003b3;: interferon-gamma, PGE2: prostaglandin E2, IDO: indoleamine 2,3-dioxygenase. HGF: hepatocyte growth factor, BDNF: brain-derived neurotrophic factor, GDNF: glial cell-derived neurotrophic, BFGF: basic fibroblast growth factor, IGF: insulin-like growth factors, VEGF: vascular endothelial growth factor, KYN: kynurenine, FOXP3: forehead box P3, STAT5: signal transducer and activator of transcription 5, C-met: hepatocyte growth factor receptor, BBB: blood&#x02013;brain barrier. The images depicted in the figure are designed by authors</p></caption><graphic xlink:href="13287_2023_3264_Fig3_HTML" id="MO3"/></fig></p><p id="Par71">MSC-derived cytokines can induce Th0 differentiation to other T cell subsets. IL-10 and TGF-&#x003b2; are competent representatives of these cytokines. Following investigations of the underlying mechanisms, it was observed that co-cultured BM-MSC with CD62L<sup>high</sup> CD44<sup>low</sup> CD4&#x02009;+&#x02009;CD25<sup>low</sup> T cell population reduced differentiation of Th0 toward Th17 through downregulation of the ROR&#x003b3;T-related signaling pathway. Researchers have demonstrated that the increase in IL-10 secretion might play a key role in this action, so that IL-10 neutralization could significantly restore the Th17 population [<xref ref-type="bibr" rid="CR112">112</xref>]. Svobodova et al. co-cultured the alloantigen-stimulated spleen cells with TGF-&#x003b2; releasing MSCs to examine the effect of MSC-derived TGF-&#x003b2; on the na&#x000ef;ve T cell differentiation. They confirmed that TGF-&#x003b2; reciprocally regulated Th17 development and its secretory cytokine, IL-17, as well as two crucial transcription factors, Foxp3 and ROR&#x003b3;T []. As a result, inducing Th0 differentiation into the Treg cell population instead of Th17 is known as another chief function of the mentioned cytokines, resulting in changing the Treg/Th17 ratio in favor of tissue hemostasis. Tregs also suppress the DC-induced Th<sub>17</sub> differentiation [<xref ref-type="bibr" rid="CR113">113</xref>].</p><p id="Par72">Inhibition of T cell proliferation is another critical mechanism induced by MSC mediators. HGF exerts its indirect T cell anti-proliferative role by regulating c-met receptors in antigen-presenting cells, especially DCs [<xref ref-type="bibr" rid="CR76">76</xref>]. However, the direct suppression effect of this receptor on Th17 remains unclear. In addition to the HGF functional assessment, another study designed by Bai et al. demonstrated improved memory deficit and functional recovery following the infusion of HGF-induced MSC secretome to EAE mouse models. Their results revealed that HGF is a pleiotropic cytokine with neurotrophic and immunomodulatory effects [<xref ref-type="bibr" rid="CR114">114</xref>]. PGE2, as another potent immunomodulatory product of MSC, can prevent the Th1 and Th17 proliferation and secretion of their inflammatory cytokines [<xref ref-type="bibr" rid="CR115">115</xref>]; meanwhile, it could be controversial depending on lymphocyte maturation status [<xref ref-type="bibr" rid="CR116">116</xref>]. IDO specifically released by human MSCs, exerts an anti-inflammatory role by inducing the production of kynurenine, a toxic metabolite against T cell proliferation and apoptosis [<xref ref-type="bibr" rid="CR117">117</xref>].</p><p id="Par73">MSC-derived cytokines inhibit T cell migration through the BBB. In addition to preventing the antigen presentation to T cells and limiting their proliferation capacity, MSC secretomes have other functional methods to inhibit neuronal degradation and disease progression in MS. Autoreactive T cells can break the BBB and migrate to the CNS neurons using matrix metalloproteinase (MMP)-9, a well-known proteolytic enzyme involved in the MS and EAE pathogenesis, which lyses the myelin sheath [<xref ref-type="bibr" rid="CR118">118</xref>]. Considering these data, inhibiting MMPs is a potential concept to develop a novel therapeutic method for neuroinflammatory diseases, especially MS [<xref ref-type="bibr" rid="CR119">119</xref>]. Researchers have indicated that MSC secretomes could relieve disease severity by preventing MMP activity [<xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR121">121</xref>]. In this regard, another study introduced MSC-secreted tissue inhibitors of metalloproteinase (TIMPs) as a potent inhibitor of MMP [<xref ref-type="bibr" rid="CR122">122</xref>].</p><p id="Par74">The immunomodulatory effect of MSCs can be partly explained by inflammasome inactivation. NALP3 is a well-known inflammasome involved in various autoimmune diseases, including MS [<xref ref-type="bibr" rid="CR122">122</xref>]. This elucidates the therapeutic effect of PDLSC-derived secretome in MS, acting similarly to the conventional immunosuppressant drugs, such as interferon-beta (IFN-&#x003b2;), and suppressing the NALP3 inflammasome and the NFk&#x003b2; signaling pathway via secreting cytokines such as IL-10 and TGF-&#x003b2; [<xref ref-type="bibr" rid="CR123">123</xref>]. The inhibitory effect of IL-10 on activated macrophages via inhibiting NALP3 was previously confirmed [<xref ref-type="bibr" rid="CR124">124</xref>]. It was reported that the main effect of IFN-&#x003b2; is immunomodulation and enhancement of BDNF levels [<xref ref-type="bibr" rid="CR125">125</xref>].</p><p id="Par75">In conclusion, MSCs can induce neuroprotection and endogenous neurogenesis at injury sites by secreting neurotrophic mediators to improve neuronal survival. Since the levels of neurotrophic factors are dramatically reduced in the CNS of MS patients, increasing their rate or at least maintaining their physiologic level seems to be a valuable therapeutic option [<xref ref-type="bibr" rid="CR126">126</xref>].</p></sec><sec id="Sec7"><title>Parkinson's disease (PD)</title><p id="Par76">Following AD, PD is known to be the most prevalent neurodegenerative disease, discovered by James Parkinson in 1817. It affects approximately 1%-3% of the population above the age of 60 [<xref ref-type="bibr" rid="CR1">1</xref>]. Among different factors involved in PD pathogenies, including disruption of the protein cleanup pathway, mitochondrial dysfunction, oxidative stress, and genetic mutation, the accumulation of &#x003b1;-synuclein protein in the Lewy bodies (LBs) is the most well-known pathological feature in the disease development [<xref ref-type="bibr" rid="CR127">127</xref>]. Following damage to the mitochondria, the toxic effect of LBs induces apoptosis in dopaminergic (DA) neurons, specifically in the substantia nigra [<xref ref-type="bibr" rid="CR128">128</xref>]. The progressive degeneration of DA neurons develops several symptoms of motor dysfunction, including postural instability, bradykinesia, and rigidity [<xref ref-type="bibr" rid="CR129">129</xref>].</p><p id="Par77">The current accepted standard therapy for PD is levodopa (L-DOPA). Though it alleviates the major symptoms, its dosage should be increased due to the inability to replace DA neurons, thus increasing its side effect. Additionally, its short half-life necessitates the use of other treatment methods [<xref ref-type="bibr" rid="CR130">130</xref>]. To the best of our knowledge and according to the US National Institutes of Health website (<ext-link ext-link-type="uri" xlink:href="http://www.clinical">http://www.clinical</ext-link>trials.gov), there are just two studies that reported cell-based treatment for PD. Li et al. reported that after fetal mesencephalic dopaminergic neuron transplantation to two PD patients, the neurons survived for over 10&#x000a0;years. However, it was revealed that the newly engrafted neurons were also affected by pathological conditions following &#x003b1;-synuclein accumulation in LBs [<xref ref-type="bibr" rid="CR131">131</xref>]. In contrast, in seven patients who had BM-MSC autologous engraftment to the sub-lateral ventricular zone via surgery, three of them showed significant improvements, and two others had their medicine dosage reduced; no evidence of tumor growth was observed in the MRI after 12&#x02013;36&#x000a0;month. Other papers focused mainly on animal models of PD [<xref ref-type="bibr" rid="CR132">132</xref>]. As the preparation step of stem cell therapy is time-consuming and the procedures for keeping the engrafted cells alive in the transplantation zone are difficult to manage, secretome-based therapy for PD has attracted remarkable attention over the past few years.</p><p id="Par78">The findings of several studies on animal models revealed that MSC-derived secretomes hold significant potential for PD treatment. Different strategies, such as inducing neuronal differentiation, increasing proliferation, raising density, and increasing neuronal viability, were reported by different research groups as having effectively improved motor dysfunctions. The discovery of the regenerative and protective effects of MSC secretomes on DA neurons has attracted a great deal of scientific attention to this new therapeutic aspect. Teixeira et al. revealed that injecting secretomes into rats&#x02019; dentate gyrus enhanced the endogenous proliferation of hippocampal neurons after seven days. They incubated human umbilical cord perivascular cells-derived secretomes with human telencephalon neural progenitor cells for five days and reported that neuronal differentiation and density increased in both mature and immature cells. NGF and FGF-2 levels increased simultaneously in that region [<xref ref-type="bibr" rid="CR77">77</xref>]. Sakane and Miyamoto introduced CHD2 as an important modulator molecule in DA neuron differentiation and proliferation through the regulation of the Wnt-&#x003b2;-catenin signaling pathway [<xref ref-type="bibr" rid="CR133">133</xref>].</p><p id="Par79">Some evidence has confirmed that MSC secretome-mediated functional recovery in DA neurons. In mouse models of PD, DA neurons progressively degenerated, and accordingly, motor coordination was impaired. The researcher verified the motor performance improvement following injecting the MSC-derived secretomes compared to the control group. However, its effects gradually decreased as time passed, probably due to local consumption. They also showed that the tyrosine hydroxylase (TH)&#x02009;+&#x02009;neurons increased in the test groups compared to those in the control group [<xref ref-type="bibr" rid="CR57">57</xref>]. The increased number of TH&#x02009;+&#x02009;neurons could be considered one of the factors involved in improving functional balancing. Following the detection of possible contributing factors in this action, F&#x000e1;bio and Teixeira introduced 21 proteins, namely BDNF, VEGF, IL-6, GDNF, cystatin-C, porcine epidermal growth factor (PEGF), galectin-1, heat-shock protein (HSP)-27, TRX1, UCHL1, semaphorin 7a (SEMA 7A), stromal cell-derived factor (SDF)-1, clustrin, CypA, CypA, CypC, DJ-1, cadherin (CDH)-2, PRDX1, UBE3A, and MMP2 by mass spectrometry [<xref ref-type="bibr" rid="CR134">134</xref>]. Similarly, Cerri et al. confirmed GDNF, BDNF, VEGF, and IL-6 as the most effective molecules in restoring the functional balance of the dopaminergic system [<xref ref-type="bibr" rid="CR135">135</xref>].</p><p id="Par80">Strong evidence has emphasized the effect of neuronal growth factors on neuronal viability following secretome therapy. It was reported that BDNF expression is reduced in the substantia nigra pars compacta (SNC) in the early stages of PD [<xref ref-type="bibr" rid="CR136">136</xref>]. Researchers have also introduced this molecule as an essential factor in the development and plasticity of DA neurons preventing neurodegeneration and increasing neuron viability and survival [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. Hence, knocking down the BDNF gene is associated with increased susceptibility and neuronal loss in DA neurons [<xref ref-type="bibr" rid="CR139">139</xref>]. GDNF is another neurotrophic molecule involved in the viability and survival of DA neurons [<xref ref-type="bibr" rid="CR140">140</xref>] through upregulating Bcl-x and Bcl-2 anti-apoptotic proteins [<xref ref-type="bibr" rid="CR141">141</xref>]. As a potent antioxidant, GDNF inhibits ROS-mediated degeneration by increasing antioxidant enzyme activity [<xref ref-type="bibr" rid="CR142">142</xref>]. IL-6, a scavenger of superoxide radicals, upregulates ROS activity, contributing to DA neurons&#x02019; protection [<xref ref-type="bibr" rid="CR143">143</xref>]. In addition, IL-6 exerted protective effects on DA neurons against MPP&#x02009;+&#x02009;-mediated toxicity [<xref ref-type="bibr" rid="CR144">144</xref>]. Thus, knocking down the IL-6 gene makes DA neurons more sensitive to methyl-phenyl-tetrahydropyridine neurotoxicity [<xref ref-type="bibr" rid="CR145">145</xref>].</p><p id="Par81">Several growth factors produced after secretome therapy have been recognized as having either a direct or indirect neuroprotective role in Parkinson&#x02019;s disease. In addition to increasing neuronal viability, BDNF and GDNF can directly protect the dopaminergic system [<xref ref-type="bibr" rid="CR146">146</xref>]. The indirect protection is provided by other growth factors like FGF-2 and EGF [<xref ref-type="bibr" rid="CR147">147</xref>]. Furthermore, certain VEGF subtypes exert protective effects in a dose-dependent manner through both mentioned mechanisms. In response to acute damages to the dopaminergic system, another important neurotrophic molecule, called PDEF [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>], has a better functional outcome and easier delivery compared to other therapeutic methods using secreted molecules like GDNF [<xref ref-type="bibr" rid="CR150">150</xref>]. PDEF exerts its effect by inducing the NF-kB signaling pathway. NF-kB, as a transcription factor, increases the expression of other neurotrophic molecules, such as BDNF and GDNF [], thereby indirectly increasing neuronal viability and survival.</p><p id="Par82">The aforementioned data shed light on the fact that secretomes can relatively compensate for neuronal loss in PD without requiring further cell transfer. Comparing MSC engraftment and secretome to the animal models of PD showed that the secretome is more efficient in increasing the number and density of TH&#x02009;+&#x02009;neurons in the striatum and neural progenitor cells area, which is probably the cause of the low survival rate of the MSCs in these regions [<xref ref-type="bibr" rid="CR151">151</xref>].</p></sec><sec id="Sec8"><title>Preclinical studies and clinical trials</title><p id="Par83">The therapeutic effects of MSC therapy and MSC-derived exosomes in animal models of neurodegenerative diseases are presented in Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>, respectively. While the preclinical results are promising, the safety and efficacy of MSC-derived secretomes in humans have not been confirmed yet.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Therapeutic effects of MSC-derived exosomes in animal models of neurodegenerative diseases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Disease</th><th align="left">Source of exosomes</th><th align="left">Therapeutic effect</th><th align="left">Refs.</th><th align="left">Year</th></tr></thead><tbody><tr><td align="left" rowspan="15">AD</td><td align="left">Mouse BM-MSCs</td><td align="left">Improved cognitive behavior</td><td align="left">[<xref ref-type="bibr" rid="CR195">195</xref>]</td><td align="left">2018</td></tr><tr><td align="left">Human UCB-MSCs</td><td align="left">Ameliorated cognitive decline; attenuated neuro-inflammation</td><td align="left">[<xref ref-type="bibr" rid="CR196">196</xref>]</td><td align="left">2018</td></tr><tr><td align="left">Human UCB-MSCs</td><td align="left">Ameliorates neural impairment</td><td align="left">[<xref ref-type="bibr" rid="CR195">195</xref>]</td><td align="left">2018</td></tr><tr><td align="left">Human UCB-MSCs</td><td align="left">Alleviated neuro-inflammation; reduced amyloid-beta deposition</td><td align="left">[<xref ref-type="bibr" rid="CR197">197</xref>]</td><td align="left">2018</td></tr><tr><td align="left">Human UCB-MSCs</td><td align="left">Repaired cognitive dysfunctions</td><td align="left">[<xref ref-type="bibr" rid="CR197">197</xref>]</td><td align="left">2018</td></tr><tr><td align="left">Mouse BM-MSCs</td><td align="left">Reduced A&#x003b2; plaque burden</td><td align="left">[<xref ref-type="bibr" rid="CR198">198</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Mouse BM-MSCs</td><td align="left">Reduced amount of dystrophic neurites in both the cortex and hippocampus</td><td align="left">[<xref ref-type="bibr" rid="CR198">198</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Mouse BM-MSCs</td><td align="left">Recovered cognition impairment</td><td align="left">[<xref ref-type="bibr" rid="CR199">199</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Not mentioned</td><td align="left">Restored cognitive function; increased learning abilities</td><td align="left">[<xref ref-type="bibr" rid="CR200">200</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Human, purchased</td><td align="left">Enhanced neurogenesis; restored cognitive function</td><td align="left">[<xref ref-type="bibr" rid="CR201">201</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Mouse BM-MSCs</td><td align="left">Reduced A&#x003b2; deposition; improved cognitive function recovery</td><td align="left">[<xref ref-type="bibr" rid="CR202">202</xref>]</td><td align="left">202</td></tr><tr><td align="left">Human AT-MSCs</td><td align="left">Induced neurogenesis; ameliorated cognitive dysfunction</td><td align="left">[<xref ref-type="bibr" rid="CR203">203</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Human UCB-MSCs</td><td align="left">Improved cognitive function</td><td align="left">[<xref ref-type="bibr" rid="CR164">164</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Human BM-MSCs</td><td align="left">Decreased microglia activation; increased dendritic spine density</td><td align="left">[<xref ref-type="bibr" rid="CR204">204</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Rat BM-MSCs</td><td align="left">Improved in destructive structural changes in the taste buds and their innervations</td><td align="left">[<xref ref-type="bibr" rid="CR205">205</xref>]</td><td align="left">2020</td></tr><tr><td align="left" rowspan="2">MS</td><td align="left">Rat BM-MSCs</td><td align="left">Decreased neural behavioral scores</td><td align="left">[<xref ref-type="bibr" rid="CR206">206</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Human BM-MSCs</td><td align="left">Reduced disease severity</td><td align="left">[<xref ref-type="bibr" rid="CR207">207</xref>]</td><td align="left">2019</td></tr><tr><td align="left" rowspan="10">PD</td><td align="left">Rat BM-MSCs</td><td align="left">Reverted motor phenotype and the neuronal organization</td><td align="left">[<xref ref-type="bibr" rid="CR208">208</xref>]</td><td align="left">2017</td></tr><tr><td align="left">Rat AT-MSCs</td><td align="left">Induced neuroprotection; Increase neuronal plasticity</td><td align="left">[<xref ref-type="bibr" rid="CR209">209</xref>]</td><td align="left">2017</td></tr><tr><td align="left">Rat BM-MSCs</td><td align="left">Neuroprotective effect on dopaminergic neuron</td><td align="left">[<xref ref-type="bibr" rid="CR210">210</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Human AT-MSCs</td><td align="left">Ameliorated neurological complications</td><td align="left">[<xref ref-type="bibr" rid="CR211">211</xref>]</td><td align="left">2019</td></tr><tr><td align="left">Human UCB-MSCs</td><td align="left">Improved neurogenesis and cognitive function</td><td align="left">[<xref ref-type="bibr" rid="CR212">212</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Rat BM-MSCs</td><td align="left">Attenuated of dopaminergic neuron loss; Improved dopamine levels in the striatum</td><td align="left">[<xref ref-type="bibr" rid="CR212">212</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Rat BM-MSCs</td><td align="left">Improved motor function</td><td align="left">[<xref ref-type="bibr" rid="CR213">213</xref>]</td><td align="left">2020</td></tr><tr><td align="left">Mouse AT-MSCs</td><td align="left">Suppressed autophagy and pyroptosis</td><td align="left">[<xref ref-type="bibr" rid="CR214">214</xref>]</td><td align="left">2021</td></tr><tr><td align="left">Mouse AT-MSCs</td><td align="left">Promoted angiogenesis of human brain microvascular endothelial cells</td><td align="left">[<xref ref-type="bibr" rid="CR215">215</xref>]</td><td align="left">2021</td></tr><tr><td align="left">Human BM-MSCs</td><td align="left">Reduced number of &#x003b1;-synuclein inclusions</td><td align="left">[<xref ref-type="bibr" rid="CR216">216</xref>]</td><td align="left">2021</td></tr></tbody></table><table-wrap-foot><p><italic>AD</italic> Alzheimer&#x02019;s disease, <italic>MS</italic> Multiple sclerosis, <italic>PD</italic> Parkinson&#x02019;s disease, <italic>BM-MSCs</italic> Bone marrow-derived mesenchymal stem cells, <italic>AD-MSCs</italic> Adipose tissue-derived mesenchymal stem cells, <italic>UCB-MSCs</italic> Umbilical cord blood-derived mesenchymal stem cells</p></table-wrap-foot></table-wrap></p><p id="Par84">Over the past decade, the therapeutic potential of MSC therapy in neurodegenerative diseases has been evaluated in various clinical trials. Table <xref rid="Tab3" ref-type="table">3</xref> presents all the clinical trials of MSC therapy in AD, PD, and MS patients listed in the US National Institutes of Health Clinical Trials Database (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>) till September 2022. Although various phase I and II clinical trials were conducted to assess the safety and efficiency of MSC therapy in neurodegenerative disease, the results should be warranted by phase III trials.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Therapeutic effects of MSC in human models of neurodegenerative diseases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Disease</th><th align="left">NCT and Phase</th><th align="left">Participants</th><th align="left">Stage</th><th align="left">Tissue source of MSC</th><th align="left">Findings</th></tr></thead><tbody><tr><td align="left" rowspan="15">AD</td><td align="left">NCT01297218 (I)</td><td align="left">9</td><td align="left">Completed</td><td align="left">Allogeneic UCB</td><td align="left">Feasible; safe; well tolerated</td></tr><tr><td align="left"><p>NCT01696591</p><p>(Long-term follow-up of NCT01297218)</p></td><td align="left">9</td><td align="left">Unknown</td><td align="left">Allogeneic UCB</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT02054208 (I/IIa)</td><td align="left">45</td><td align="left">Completed</td><td align="left">Allogeneic UCB</td><td align="left">Not yet published</td></tr><tr><td align="left"><p>NCT03172117</p><p>(Long-term follow-up of NCT02054208)</p></td><td align="left">45</td><td align="left">Unknown</td><td align="left">Allogeneic UCB</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT03117738 (I/II)</td><td align="left">21</td><td align="left">Completed</td><td align="left">Autologous AD</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT04228666 (I/IIa)</td><td align="left">24</td><td align="left">Withdrawn</td><td align="left">Autologous AD</td><td align="left">Not yet reported</td></tr><tr><td align="left">NCT02600130 (I)</td><td align="left">33</td><td align="left">Active</td><td align="left">Longeveron</td><td align="left">NA</td></tr><tr><td align="left">NCT04855955</td><td align="left">1</td><td align="left">Available</td><td align="left">Autologous AD</td><td align="left">NA</td></tr><tr><td align="left">NCT02833792 (IIa)</td><td align="left">40</td><td align="left">Recruiting</td><td align="left"><p>Allogeneic</p><p>(not mentioned)</p></td><td align="left">NA</td></tr><tr><td align="left">NCT04040348 (I)</td><td align="left">6</td><td align="left">Recruiting</td><td align="left">Allogeneic UCB</td><td align="left">NA</td></tr><tr><td align="left">NCT02899091 (I/IIa)</td><td align="left">24</td><td align="left">Recruiting</td><td align="left">Allogenic placenta</td><td align="left">NA</td></tr><tr><td align="left">NCT04684602 (I/II)</td><td align="left">5,000</td><td align="left">Recruiting</td><td align="left">Allogenic UCB</td><td align="left">NA</td></tr><tr><td align="left">NCT04482413 (IIb)</td><td align="left">80</td><td align="left">Not yet recruiting</td><td align="left">Autologous AD</td><td align="left">NA</td></tr><tr><td align="left">NCT01547689 (I/II)</td><td align="left">30</td><td align="left">Unknown</td><td align="left">Allogenic UCB</td><td align="left">NA</td></tr><tr><td align="left">NCT02672306 (I/II)</td><td align="left">16</td><td align="left">Unknown</td><td align="left">Allogenic UCB</td><td align="left">NA</td></tr><tr><td align="left" rowspan="22">MS</td><td align="left">NCT01745783 (I/II)</td><td align="left">26</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left">Safety and efficacy</td></tr><tr><td align="left">NCT02326935 (I)</td><td align="left">2</td><td align="left">Terminated</td><td align="left">Autologous AD</td><td align="left">NA</td></tr><tr><td align="left">NCT03799718 (II)</td><td align="left">20</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT01854957 (I/II)</td><td align="left">20</td><td align="left">Recruiting</td><td align="left">Autologous BM</td><td align="left">NA</td></tr><tr><td align="left">NCT01364246 (I/II)</td><td align="left">20</td><td align="left">Recruiting</td><td align="left">Allogeneic UC</td><td align="left">NA</td></tr><tr><td align="left">NCT01377870 (I/II)</td><td align="left">22</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT00395200 (I/II)</td><td align="left">10</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left"><p>Safe; feasible;</p><p>positive therapeutic outcomes</p></td></tr><tr><td align="left">NCT02403947 (I/II)</td><td align="left">1</td><td align="left">Terminated</td><td align="left">Autologous BM</td><td align="left">NA</td></tr><tr><td align="left">NCT01895439 (I/II)</td><td align="left">13</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left">NA</td></tr><tr><td align="left">NCT01933802 (I)</td><td align="left">20</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left"><p>Safe; well tolerated;</p><p>minor adverse events included transient fever and mild headaches</p></td></tr><tr><td align="left">NCT02034188 (I)</td><td align="left">20</td><td align="left">Completed</td><td align="left">Allogeneic UC</td><td align="left">Feasible; safe</td></tr><tr><td align="left">NCT02035514 (I/II)</td><td align="left">9</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left">Not applicable</td></tr><tr><td align="left">NCT02239393 (I)</td><td align="left">31</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left">Safety and efficacy</td></tr><tr><td align="left">NCT01056471 (I/II)</td><td align="left">30</td><td align="left">Completed</td><td align="left">Autologous AT</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT03326505 (I/II)</td><td align="left">60</td><td align="left">Completed</td><td align="left">Allogeneic UC</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT01730547 (I/II)</td><td align="left">15</td><td align="left">Recruiting</td><td align="left">Autologous BM</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT02495766 (I/II)</td><td align="left">8</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT02166021 (II)</td><td align="left">48</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left"><p>Well-tolerated;</p><p>induced short-term beneficial effects</p></td></tr><tr><td align="left">NCT01606215 (I, II)</td><td align="left">21</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT00781872 (I, II)</td><td align="left">24</td><td align="left">Completed</td><td align="left">Autologous BM</td><td align="left"><p>Clinically feasible; safe;</p><p>induced immunomodulatory effects</p></td></tr><tr><td align="left">NCT03069170 (I)</td><td align="left">50</td><td align="left">Recruiting</td><td align="left">Autologous BM</td><td align="left">Not yet published</td></tr><tr><td align="left">NCT02157064 (NA)</td><td align="left">221</td><td align="left">Unknown</td><td align="left">Autologous AT</td><td align="left">NA</td></tr><tr><td align="left" rowspan="14">PD</td><td align="left">NCT01453803 (I/II)</td><td align="left">0</td><td align="left">Withdrawn</td><td align="left">Autologous AT</td><td align="left">NA</td></tr><tr><td align="left">NCT02184546</td><td align="left">75</td><td align="left">Not yet recruiting</td><td align="left">Autologous AT</td><td align="left">NA</td></tr><tr><td align="left">NCT04064983</td><td align="left">Unknown</td><td align="left">No expanded access</td><td align="left">Autologous AT</td><td align="left">NA</td></tr><tr><td align="left">NCT02611167 (I/II)</td><td align="left">20</td><td align="left">Completed</td><td align="left">Allogeneic BM</td><td align="left">NA</td></tr><tr><td align="left">NCT00976430</td><td align="left">5</td><td align="left">Terminated</td><td align="left">Autologous BM</td><td align="left">NA</td></tr><tr><td align="left">NCT01446614 (I/II)</td><td align="left">20</td><td align="left">recruiting</td><td align="left">Autologous BM</td><td align="left">NA</td></tr><tr><td align="left">NCT03550183 (I)</td><td align="left">20</td><td align="left">recruiting</td><td align="left">Allogeneic UC</td><td align="left">NA</td></tr><tr><td align="left">NCT04506073 (II)</td><td align="left">45</td><td align="left">Not yet recruiting</td><td align="left">Not mentioned</td><td align="left">NA</td></tr><tr><td align="left">NCT04928287 (II)</td><td align="left">24</td><td align="left">Not yet recruiting</td><td align="left">Allogeneic AT</td><td align="left">NA</td></tr><tr><td align="left">NCT04995081 (II)</td><td align="left">60</td><td align="left">recruiting</td><td align="left">Allogeneic AT</td><td align="left">NA</td></tr><tr><td align="left">NCT03684122 (I/II)</td><td align="left">10</td><td align="left">Not yet recruiting</td><td align="left">Allogeneic UCB</td><td align="left">NA</td></tr><tr><td align="left">NCT04146519 (II/III)</td><td align="left">50</td><td align="left">Recruiting</td><td align="left"><p>Autologous</p><p>(not mentioned)</p></td><td align="left">NA</td></tr><tr><td align="left">NCT05094011 (I)</td><td align="left">9</td><td align="left">Not yet recruiting</td><td align="left">Autologous AT</td><td align="left">NA</td></tr><tr><td align="left">NCT04876326 (NA)</td><td align="left">15</td><td align="left">Recruiting</td><td align="left"><p>Autologous AT,</p><p>Allogeneic UC</p></td><td align="left">NA</td></tr></tbody></table><table-wrap-foot><p><italic>AD</italic> Alzheimer&#x02019;s disease, <italic>MS</italic> Multiple sclerosis, <italic>PD</italic> Parkinson&#x02019;s disease, <italic>UCB</italic> Umbilical cord blood, <italic>AD-MSCs</italic> Adipose tissue, <italic>BM-MSCs</italic> Bone marrow, <italic>NA</italic> Not applicable</p></table-wrap-foot></table-wrap></p><p id="Par85">Despite all preclinical studies demonstrating the efficiency of MSC-derived exosomes in neurodegenerative diseases, their clinical utility has yet to be demonstrated. There are just phase I and II clinical trials initiated to evaluate the safety and efficacy of exosomes secreted from allogeneic adipose tissue-derived MSC in AD patients (NCT04388982).</p></sec></sec><sec id="Sec9"><title>Conclusion</title><p id="Par86">MSC-derived secretomes can be used as a promising therapeutic approach in the treatment of neurodegenerative disorders for which no treatment has yet been introduced. This cell-free strategy can solve complications due to MSCs&#x02019; migration to the injury site and their differentiation. Because MSCs' beneficial properties are dependent on their ability to deliver their content, MSC-derived secretomes can be as effective as MSCs transplantation in activating the pro-survival and anti-apoptotic signals, leading to improved tissue neuron regeneration. Indeed, MSC-derived secretomes serve as an information transporter from MSCs to neurons.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CNS</term><def><p id="Par4">Central nervous system</p></def></def-item><def-item><term>MS</term><def><p id="Par5">Multiple sclerosis</p></def></def-item><def-item><term>AD</term><def><p id="Par6">Alzheimer's disease</p></def></def-item><def-item><term>NMDA</term><def><p id="Par7">N-Methyl-D-aspartate</p></def></def-item><def-item><term>ISCT</term><def><p id="Par8">International Society of Cell Therapy</p></def></def-item><def-item><term>ALS</term><def><p id="Par9">Amyotrophic lateral</p></def></def-item><def-item><term>IV</term><def><p id="Par10">Intravenous</p></def></def-item><def-item><term>NGF</term><def><p id="Par11">Nerve growth factor</p></def></def-item><def-item><term>GDNF</term><def><p id="Par12">Glial cell-derived neurotrophic factor</p></def></def-item><def-item><term>BDNF</term><def><p id="Par13">Brain-derived neurotrophic factor</p></def></def-item><def-item><term>NT</term><def><p id="Par14">Neurotrophin</p></def></def-item><def-item><term>VEGF</term><def><p id="Par15">Vascular endothelial growth factor</p></def></def-item><def-item><term>HGF</term><def><p id="Par16">Hepatocyte growth factor</p></def></def-item><def-item><term>FGF</term><def><p id="Par17">Fibroblast growth factor</p></def></def-item><def-item><term>PEDF</term><def><p id="Par18">Pigment epithelium-derived factor</p></def></def-item><def-item><term>IGF</term><def><p id="Par19">Insulin-like growth factor</p></def></def-item><def-item><term>TGF-&#x003b2;</term><def><p id="Par20">Transforming growth factor-beta</p></def></def-item><def-item><term>IL</term><def><p id="Par21">Interleukin</p></def></def-item><def-item><term>IDO</term><def><p id="Par22">Indoleamine 2,3-dioxygenase</p></def></def-item><def-item><term>PGE2</term><def><p id="Par23">Prostaglandin E2</p></def></def-item><def-item><term>HLA</term><def><p id="Par24">Human leukocyte antigen</p></def></def-item><def-item><term>MHC</term><def><p id="Par25">Major histocompatibility complex</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p id="Par26">Interferon &#x003b3;</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p id="Par27">Tumor necrosis factor-&#x003b1;</p></def></def-item><def-item><term>TSG-6</term><def><p id="Par28">TNF-&#x003b1;-stimulated protein 6</p></def></def-item><def-item><term>NK</term><def><p id="Par29">Natural killer cells</p></def></def-item><def-item><term>BBB</term><def><p id="Par30">Blood&#x02013;brain barrier</p></def></def-item><def-item><term>A&#x003b2;</term><def><p id="Par31">Amyloid-beta</p></def></def-item><def-item><term>NFT</term><def><p id="Par32">Neurofibrillary tangles</p></def></def-item><def-item><term>IFN-&#x003b2;</term><def><p id="Par33">Interferon-beta</p></def></def-item><def-item><term>MG</term><def><p id="Par34">Microglia</p></def></def-item><def-item><term>AC</term><def><p id="Par35">Astrocytes</p></def></def-item><def-item><term>TLR</term><def><p id="Par36">Toll-like receptor</p></def></def-item><def-item><term>CCL5</term><def><p id="Par37">Chemokine ligand 5</p></def></def-item><def-item><term>ICAM-1</term><def><p id="Par38">Intracellular adhesion molecule-1</p></def></def-item><def-item><term>MMP</term><def><p id="Par39">Matrix metalloproteinase</p></def></def-item><def-item><term>LB</term><def><p id="Par40">Lewy body</p></def></def-item><def-item><term>TH</term><def><p id="Par41">Tyrosine hydroxylase</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>All authors read and approved the final manuscript.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>MG made the literature review and wrote the manuscript draft, ER edited the manuscript draft scientifically, MM reviewed and edited the manuscript, BF contributed to writing the manuscript draft, and PA and KS supervised the data collection, wrote the manuscript draft, and finalized the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This article was partly funded by Tabriz Stem Cell Research Center at the Tabriz University of Medical Sciences, Iran (Grant/Award Number: 63912). (The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.)</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par87">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par88">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par89">All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>DK</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name></person-group><article-title>Parkinson disease epidemiology, pathology, genetics, and pathophysiology</article-title><source>Clin Geriatr Med</source><year>2020</year><volume>36</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.cger.2019.08.002</pub-id><pub-id pub-id-type="pmid">31733690</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twohig</surname><given-names>D</given-names></name><name><surname>Nielsen</surname><given-names>HM</given-names></name></person-group><article-title>&#x003b1;-synuclein in the pathophysiology of Alzheimer&#x02019;s disease</article-title><source>Mol Neurodegener</source><year>2019</year><volume>14</volume><issue>1</issue><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1186/s13024-019-0320-x</pub-id><pub-id pub-id-type="pmid">30630532</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Z&#x000e9;phir</surname><given-names>H</given-names></name></person-group><article-title>Progress in understanding the pathophysiology of multiple sclerosis</article-title><source>Revue Neurol</source><year>2018</year><volume>174</volume><issue>6</issue><fpage>358</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.neurol.2018.03.006</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>E</given-names></name><name><surname>Devasahayam</surname><given-names>G</given-names></name></person-group><article-title>Neurodegeneration by oxidative stress: a review on prospective use of small molecules for neuroprotection</article-title><source>Mol Biol Rep</source><year>2020</year><volume>47</volume><issue>4</issue><fpage>3133</fpage><lpage>3140</lpage><pub-id pub-id-type="doi">10.1007/s11033-020-05354-1</pub-id><pub-id pub-id-type="pmid">32162127</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>LG</given-names></name><name><surname>Cole</surname><given-names>TB</given-names></name><name><surname>Dao</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>Y-C</given-names></name><name><surname>Coburn</surname><given-names>J</given-names></name><name><surname>Garrick</surname><given-names>JM</given-names></name></person-group><article-title>Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders</article-title><source>Pharmacol Ther</source><year>2020</year><volume>210</volume><fpage>107523</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107523</pub-id><pub-id pub-id-type="pmid">32165138</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JG</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Jeong</surname><given-names>M</given-names></name><name><surname>Oh</surname><given-names>MS</given-names></name></person-group><article-title>Pharmacotherapeutic potential of ginger and its compounds in age-related neurological disorders</article-title><source>Pharmacol Ther</source><year>2018</year><volume>182</volume><fpage>56</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.08.010</pub-id><pub-id pub-id-type="pmid">28842272</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmer</surname><given-names>A</given-names></name><name><surname>Youngblood</surname><given-names>A</given-names></name><name><surname>Adnane</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>BJ</given-names></name><name><surname>Goldsmith</surname><given-names>DR</given-names></name></person-group><article-title>Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: a review of the literature and recommendations for the COVID-19 pandemic</article-title><source>Brain Behav Immun</source><year>2021</year><volume>91</volume><fpage>756</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.10.024</pub-id><pub-id pub-id-type="pmid">33152446</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>J</given-names></name><name><surname>Salhotra</surname><given-names>S</given-names></name><name><surname>Goswami</surname><given-names>P</given-names></name><name><surname>Akhter</surname><given-names>J</given-names></name><name><surname>Jahan</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bisphenol A triggers axonal injury and myelin degeneration with concomitant neurobehavioral toxicity in C57BL/6J male mice</article-title><source>Toxicology</source><year>2019</year><volume>428</volume><fpage>152299</fpage><pub-id pub-id-type="doi">10.1016/j.tox.2019.152299</pub-id><pub-id pub-id-type="pmid">31574244</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cervellati</surname><given-names>C</given-names></name><name><surname>Trentini</surname><given-names>A</given-names></name><name><surname>Pecorelli</surname><given-names>A</given-names></name><name><surname>Valacchi</surname><given-names>G</given-names></name></person-group><article-title>Inflammation in neurological disorders: the thin boundary between brain and periphery</article-title><source>Antioxid Redox Signal</source><year>2020</year><volume>33</volume><issue>3</issue><fpage>191</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1089/ars.2020.8076</pub-id><pub-id pub-id-type="pmid">32143546</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skovronsky</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications</article-title><source>Annu Rev Pathol Mech Dis</source><year>2006</year><volume>1</volume><fpage>151</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1146/annurev.pathol.1.110304.100113</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matesanz</surname><given-names>AI</given-names></name><name><surname>Caballero</surname><given-names>AB</given-names></name><name><surname>Lorenzo</surname><given-names>C</given-names></name><name><surname>Espargaro</surname><given-names>A</given-names></name><name><surname>Sabat&#x000e9;</surname><given-names>R</given-names></name><name><surname>Quiroga</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Thiosemicarbazone derivatives as inhibitors of amyloid-&#x003b2; aggregation: effect of metal coordination</article-title><source>Inorg Chem</source><year>2020</year><volume>59</volume><issue>10</issue><fpage>6978</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1021/acs.inorgchem.0c00467</pub-id><pub-id pub-id-type="pmid">32369695</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><name><surname>Volkmann</surname><given-names>J</given-names></name><etal/></person-group><article-title>Parkinson disease</article-title><source>Nat Rev Dis Primers</source><year>2017</year><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.13</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulshreshtha</surname><given-names>A</given-names></name><name><surname>Piplani</surname><given-names>P</given-names></name></person-group><article-title>Current pharmacotherapy and putative disease-modifying therapy for Alzheimer&#x02019;s disease</article-title><source>Neurol Sci</source><year>2016</year><volume>37</volume><issue>9</issue><fpage>1403</fpage><lpage>1435</lpage><pub-id pub-id-type="doi">10.1007/s10072-016-2625-7</pub-id><pub-id pub-id-type="pmid">27250365</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giossi</surname><given-names>R</given-names></name><name><surname>Carrara</surname><given-names>F</given-names></name><name><surname>Mazzari</surname><given-names>M</given-names></name><name><surname>Re</surname><given-names>FL</given-names></name><name><surname>Senatore</surname><given-names>M</given-names></name><name><surname>Schicchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Overall efficacy and safety of safinamide in Parkinson&#x02019;s disease: a systematic review and a meta-analysis</article-title><source>Clin Drug Investig</source><year>2021</year><volume>41</volume><fpage>321</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1007/s40261-021-01011-y</pub-id><pub-id pub-id-type="pmid">33674954</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>JM</given-names></name><name><surname>Fell</surname><given-names>MJ</given-names></name></person-group><article-title>Current approaches to the treatment of Parkinson&#x02019;s disease</article-title><source>Bioorg Med Chem Lett</source><year>2017</year><volume>27</volume><issue>18</issue><fpage>4247</fpage><lpage>4255</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2017.07.075</pub-id><pub-id pub-id-type="pmid">28869077</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname><given-names>R</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name></person-group><article-title>Multiple sclerosis&#x02013;a review</article-title><source>Eur J Neurol</source><year>2019</year><volume>26</volume><issue>1</issue><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/ene.13819</pub-id><pub-id pub-id-type="pmid">30300457</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JA</given-names></name><name><surname>Imrey</surname><given-names>PB</given-names></name><name><surname>Planchon</surname><given-names>SM</given-names></name><name><surname>Bermel</surname><given-names>RA</given-names></name><name><surname>Fisher</surname><given-names>E</given-names></name><name><surname>Fox</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis</article-title><source>Mult Scler J</source><year>2018</year><volume>24</volume><issue>4</issue><fpage>501</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1177/1352458517703802</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comi</surname><given-names>G</given-names></name><name><surname>Radaelli</surname><given-names>M</given-names></name><name><surname>Soelberg</surname><given-names>SP</given-names></name></person-group><article-title>Evolving concepts in the treatment of relapsing multiple sclerosis</article-title><source>Lancet</source><year>2017</year><volume>389</volume><issue>10076</issue><fpage>1347</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32388-1</pub-id><pub-id pub-id-type="pmid">27889192</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbaszadeh</surname><given-names>H</given-names></name><name><surname>Ghorbani</surname><given-names>F</given-names></name><name><surname>Derakhshani</surname><given-names>M</given-names></name><name><surname>Movassaghpour</surname><given-names>AA</given-names></name><name><surname>Yousefi</surname><given-names>M</given-names></name><name><surname>Talebi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Regenerative potential of Wharton's jelly-derived mesenchymal stem cells: a new horizon of stem cell therapy</article-title><source>J Cell Physiol</source><year>2020</year><volume>235</volume><issue>12</issue><fpage>9230</fpage><lpage>9240</lpage><pub-id pub-id-type="doi">10.1002/jcp.29810</pub-id><pub-id pub-id-type="pmid">32557631</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viswanathan</surname><given-names>C</given-names></name><name><surname>Kulkarni</surname><given-names>R</given-names></name><name><surname>Bopardikar</surname><given-names>A</given-names></name><name><surname>Ramdasi</surname><given-names>S</given-names></name></person-group><article-title>Significance of CD34 negative hematopoietic stem cells and CD34 positive mesenchymal stem cells&#x02013;a valuable dimension to the current understanding</article-title><source>Curr Stem Cell Res Ther</source><year>2017</year><volume>12</volume><issue>6</issue><fpage>476</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.2174/1574888X12666170502095625</pub-id><pub-id pub-id-type="pmid">28464788</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C-SS</given-names></name><name><surname>Xin</surname><given-names>Z-CC</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Lue</surname><given-names>TF</given-names></name></person-group><article-title>Commonly used mesenchymal stem cell markers and tracking labels: limitations and challenges</article-title><source>Histol Histopathol</source><year>2013</year><volume>28</volume><issue>9</issue><fpage>1109</fpage><pub-id pub-id-type="pmid">23588700</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashemi Goradel</surname><given-names>N</given-names></name><name><surname>Darabi</surname><given-names>M</given-names></name><name><surname>Shamsasenjan</surname><given-names>K</given-names></name><name><surname>Ejtehadifar</surname><given-names>M</given-names></name><name><surname>Zahedi</surname><given-names>S</given-names></name></person-group><article-title>Methods of liver stem cell therapy in rodents as models of human liver regeneration in hepatic failure</article-title><source>Adv Pharm Bull</source><year>2015</year><volume>5</volume><issue>3</issue><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.15171/apb.2015.041</pub-id><pub-id pub-id-type="pmid">26504749</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrenko</surname><given-names>Y</given-names></name><name><surname>Vackova</surname><given-names>I</given-names></name><name><surname>Kekulova</surname><given-names>K</given-names></name><name><surname>Chudickova</surname><given-names>M</given-names></name><name><surname>Koci</surname><given-names>Z</given-names></name><name><surname>Turnovcova</surname><given-names>K</given-names></name><etal/></person-group><article-title>A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41598-020-61167-z</pub-id><pub-id pub-id-type="pmid">31913322</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>SA</given-names></name><name><surname>Naik</surname><given-names>C</given-names></name><name><surname>Cahill</surname><given-names>PA</given-names></name><name><surname>Bhonde</surname><given-names>RR</given-names></name></person-group><article-title>Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis</article-title><source>Cell Mol Life Sci</source><year>2020</year><volume>77</volume><issue>2</issue><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03268-1</pub-id><pub-id pub-id-type="pmid">31468060</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squillaro</surname><given-names>T</given-names></name><name><surname>Peluso</surname><given-names>G</given-names></name><name><surname>Galderisi</surname><given-names>U</given-names></name></person-group><article-title>Clinical trials with mesenchymal stem cells: an update</article-title><source>Cell Transplant</source><year>2016</year><volume>25</volume><issue>5</issue><fpage>829</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.3727/096368915X689622</pub-id><pub-id pub-id-type="pmid">26423725</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential</article-title><source>Cell Mol Life Sci</source><year>2016</year><volume>73</volume><issue>17</issue><fpage>3311</fpage><lpage>3321</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2229-7</pub-id><pub-id pub-id-type="pmid">27141940</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadian</surname><given-names>M</given-names></name><name><surname>Shamsasenjan</surname><given-names>K</given-names></name><name><surname>Lotfi Nezhad</surname><given-names>P</given-names></name><name><surname>Talebi</surname><given-names>M</given-names></name><name><surname>Jahedi</surname><given-names>M</given-names></name><name><surname>Nickkhah</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mesenchymal stem cells: new aspect in cell-based regenerative therapy</article-title><source>Adv Pharm Bull</source><year>2013</year><volume>3</volume><issue>2</issue><fpage>433</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">24312873</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timari</surname><given-names>H</given-names></name><name><surname>Shamsasenjan</surname><given-names>K</given-names></name><name><surname>Movassaghpour</surname><given-names>A</given-names></name><name><surname>Akbarzadehlaleh</surname><given-names>P</given-names></name><name><surname>Pashoutan Sarvar</surname><given-names>D</given-names></name><name><surname>Aqmasheh</surname><given-names>S</given-names></name></person-group><article-title>The effect of mesenchymal stem cell-derived extracellular vesicles on hematopoietic stem cells fate</article-title><source>Adv Pharm Bull</source><year>2017</year><volume>7</volume><issue>4</issue><fpage>531</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.15171/apb.2017.065</pub-id><pub-id pub-id-type="pmid">29399543</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name></person-group><article-title>Mesenchymal stromal cells suppress hippocampal neuron autophagy stress induced by hypoxic-ischemic brain damage: the possible role of endogenous IL-6 secretion</article-title><source>Neural Plast</source><year>2020</year><pub-id pub-id-type="doi">10.1155/2020/8822579</pub-id><pub-id pub-id-type="pmid">33299396</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pach&#x000f3;n-Pe&#x000f1;a</surname><given-names>G</given-names></name><name><surname>Serena</surname><given-names>C</given-names></name><name><surname>Ejarque</surname><given-names>M</given-names></name><name><surname>Petriz</surname><given-names>J</given-names></name><name><surname>Duran</surname><given-names>X</given-names></name><name><surname>Oliva-Olivera</surname><given-names>W</given-names></name><etal/></person-group><article-title>Obesity determines the immunophenotypic profile and functional characteristics of human mesenchymal stem cells from adipose tissue</article-title><source>Stem Cells Transl Med</source><year>2016</year><volume>5</volume><issue>4</issue><fpage>464</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.5966/sctm.2015-0161</pub-id><pub-id pub-id-type="pmid">26956208</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sykov&#x000e1;</surname><given-names>E</given-names></name><name><surname>Rychmach</surname><given-names>P</given-names></name><name><surname>Drahor&#x000e1;dov&#x000e1;</surname><given-names>I</given-names></name><name><surname>Konr&#x000e1;dov&#x000e1;</surname><given-names>&#x00160;</given-names></name><name><surname>R&#x0016f;&#x0017e;i&#x0010d;kov&#x000e1;</surname><given-names>K</given-names></name><name><surname>Vo&#x00159;&#x000ed;&#x00161;ek</surname><given-names>I</given-names></name><etal/></person-group><article-title>Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase I/IIa clinical trial</article-title><source>Cell Transplant</source><year>2017</year><volume>26</volume><issue>4</issue><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.3727/096368916X693716</pub-id><pub-id pub-id-type="pmid">27938483</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramowski</surname><given-names>P</given-names></name><name><surname>Krasemann</surname><given-names>S</given-names></name><name><surname>Ernst</surname><given-names>T</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Ittrich</surname><given-names>H</given-names></name><name><surname>Schweizer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mesenchymal stromal/stem cells do not ameliorate experimental autoimmune encephalomyelitis and are not detectable in the central nervous system of transplanted mice</article-title><source>Stem Cells Dev</source><year>2016</year><volume>25</volume><issue>15</issue><fpage>1134</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1089/scd.2016.0020</pub-id><pub-id pub-id-type="pmid">27250994</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neirinckx</surname><given-names>V</given-names></name><name><surname>Agirman</surname><given-names>G</given-names></name><name><surname>Coste</surname><given-names>C</given-names></name><name><surname>Marquet</surname><given-names>A</given-names></name><name><surname>Dion</surname><given-names>V</given-names></name><name><surname>Rogister</surname><given-names>B</given-names></name><etal/></person-group><article-title>Adult bone marrow mesenchymal and neural crest stem cells are chemoattractive and accelerate motor recovery in a mouse model of spinal cord injury</article-title><source>Stem Cell Res Ther</source><year>2015</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1186/s13287-015-0202-2</pub-id><pub-id pub-id-type="pmid">25559585</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrepfer</surname><given-names>S</given-names></name><name><surname>Deuse</surname><given-names>T</given-names></name><name><surname>Reichenspurner</surname><given-names>H</given-names></name><name><surname>Fischbein</surname><given-names>MP</given-names></name><name><surname>Robbins</surname><given-names>RC</given-names></name><name><surname>Pelletier</surname><given-names>MP</given-names></name></person-group><article-title>Stem cell transplantation: the lung barrier</article-title><source>Transpl Proc</source><year>2007</year><volume>39</volume><issue>2</issue><fpage>573</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2006.12.019</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santamaria</surname><given-names>G</given-names></name><name><surname>Brandi</surname><given-names>E</given-names></name><name><surname>Vitola</surname><given-names>P</given-names></name><name><surname>Grandi</surname><given-names>F</given-names></name><name><surname>Ferrara</surname><given-names>G</given-names></name><name><surname>Pischiutta</surname><given-names>F</given-names></name></person-group><article-title>Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer&#x02019;s mice</article-title><source>Cell Death Differ</source><year>2021</year><volume>28</volume><issue>1</issue><fpage>203</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-0592-2</pub-id><pub-id pub-id-type="pmid">32704089</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beer</surname><given-names>L</given-names></name><name><surname>Mildner</surname><given-names>M</given-names></name><name><surname>Ankersmit</surname><given-names>HJ</given-names></name></person-group><article-title>Cell secretome based drug substances in regenerative medicine: when regulatory affairs meet basic science</article-title><source>Ann Transl Med</source><year>2017</year><volume>5</volume><issue>7</issue><fpage>170</fpage><pub-id pub-id-type="doi">10.21037/atm.2017.03.50</pub-id><pub-id pub-id-type="pmid">28480206</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marote</surname><given-names>A</given-names></name><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Mendes-Pinheiro</surname><given-names>B</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name></person-group><article-title>MSCs-derived exosomes: cell-secreted nanovesicles with regenerative potential</article-title><source>Front Pharmacol</source><year>2016</year><volume>7</volume><fpage>231</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00231</pub-id><pub-id pub-id-type="pmid">27536241</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaput</surname><given-names>N</given-names></name><name><surname>Th&#x000e9;ry</surname><given-names>C</given-names></name></person-group><article-title>Exosomes: immune properties and potential clinical implementations</article-title><source>Semin Immunopathol</source><year>2011</year><volume>33</volume><issue>5</issue><fpage>419</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1007/s00281-010-0233-9</pub-id><pub-id pub-id-type="pmid">21174094</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorabi</surname><given-names>AM</given-names></name><name><surname>Kiaie</surname><given-names>N</given-names></name><name><surname>Barreto</surname><given-names>GE</given-names></name><name><surname>Read</surname><given-names>MI</given-names></name><name><surname>Tafti</surname><given-names>HA</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name></person-group><article-title>The therapeutic potential of mesenchymal stem cell&#x02013;derived exosomes in treatment of neurodegenerative diseases</article-title><source>Mol Neurobiol</source><year>2019</year><volume>56</volume><issue>12</issue><fpage>8157</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1007/s12035-019-01663-0</pub-id><pub-id pub-id-type="pmid">31197655</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKelvey</surname><given-names>KJ</given-names></name><name><surname>Powell</surname><given-names>KL</given-names></name><name><surname>Ashton</surname><given-names>AW</given-names></name><name><surname>Morris</surname><given-names>JM</given-names></name><name><surname>McCracken</surname><given-names>SA</given-names></name></person-group><article-title>Exosomes: mechanisms of uptake</article-title><source>J Circ Biomark</source><year>2015</year><volume>4</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.5772/61186</pub-id><pub-id pub-id-type="pmid">28936243</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>ED</given-names></name><name><surname>Mendes</surname><given-names>SS</given-names></name><name><surname>Assun&#x000e7;&#x000e3;o-Silva</surname><given-names>RC</given-names></name><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Pires</surname><given-names>AO</given-names></name><name><surname>Anjo</surname><given-names>SI</given-names></name></person-group><article-title>Co-transplantation of adipose tissue-derived stromal cells and olfactory ensheathing cells for spinal cord injury repair</article-title><source>Stem Cells</source><year>2018</year><volume>36</volume><issue>5</issue><fpage>696</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1002/stem.2785</pub-id><pub-id pub-id-type="pmid">29352743</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gugliandolo</surname><given-names>A</given-names></name><name><surname>Mazzon</surname><given-names>E</given-names></name></person-group><article-title>Dental mesenchymal stem cell secretome: an intriguing approach for neuroprotection and neuroregeneration</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>456</fpage><pub-id pub-id-type="doi">10.3390/ijms23010456</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vila&#x000e7;a-Faria</surname><given-names>H</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name><name><surname>Teixeira</surname><given-names>FG</given-names></name></person-group><article-title>Mesenchymal stem cells-derived exosomes: a new possible therapeutic strategy for Parkinson&#x02019;s disease?</article-title><source>Cells</source><year>2019</year><volume>8</volume><issue>2</issue><fpage>118</fpage><pub-id pub-id-type="doi">10.3390/cells8020118</pub-id><pub-id pub-id-type="pmid">30717429</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>X-L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>Q-L</given-names></name></person-group><article-title>Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy</article-title><source>Cell Mol Life Sci</source><year>2020</year><volume>77</volume><issue>14</issue><fpage>2771</fpage><lpage>2794</lpage><pub-id pub-id-type="doi">10.1007/s00018-020-03454-6</pub-id><pub-id pub-id-type="pmid">31965214</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrell</surname><given-names>CR</given-names></name><name><surname>Fellabaum</surname><given-names>C</given-names></name><name><surname>Jovicic</surname><given-names>N</given-names></name><name><surname>Djonov</surname><given-names>V</given-names></name><name><surname>Arsenijevic</surname><given-names>N</given-names></name><name><surname>Volarevic</surname><given-names>V</given-names></name></person-group><article-title>Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome</article-title><source>Cells</source><year>2019</year><volume>8</volume><issue>5</issue><fpage>467</fpage><pub-id pub-id-type="doi">10.3390/cells8050467</pub-id><pub-id pub-id-type="pmid">31100966</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansoor</surname><given-names>SR</given-names></name><name><surname>Zabihi</surname><given-names>E</given-names></name><name><surname>Ghasemi-Kasman</surname><given-names>M</given-names></name></person-group><article-title>The potential use of mesenchymal stem cells for the treatment of multiple sclerosis</article-title><source>Life Sci</source><year>2019</year><volume>235</volume><fpage>116830</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.116830</pub-id><pub-id pub-id-type="pmid">31487529</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H-J</given-names></name><name><surname>Lee</surname><given-names>J-H</given-names></name><name><surname>Kim</surname><given-names>S-H</given-names></name></person-group><article-title>Therapeutic effects of human mesenchymal stem cells on traumatic brain injury in rats: secretion of neurotrophic factors and inhibition of apoptosis</article-title><source>J Neurotrauma</source><year>2010</year><volume>27</volume><issue>1</issue><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1089/neu.2008.0818</pub-id><pub-id pub-id-type="pmid">19508155</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redondo-Castro</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Martuscelli</surname><given-names>L</given-names></name><name><surname>Aoulad-Ali</surname><given-names>S</given-names></name><name><surname>Rothwell</surname><given-names>NJ</given-names></name></person-group><article-title>Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro</article-title><source>Stem Cell Res Therapy</source><year>2017</year><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/s13287-017-0531-4</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name></person-group><article-title>Pre-conditioned mesenchymal stem cells: a better way for cell-based therapy</article-title><source>Stem cell Res Therapy</source><year>2013</year><volume>4</volume><issue>3</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1186/scrt213</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahbaran</surname><given-names>M</given-names></name><name><surname>Zekiy</surname><given-names>AO</given-names></name><name><surname>Bahramali</surname><given-names>M</given-names></name><name><surname>Jahangir</surname><given-names>M</given-names></name><name><surname>Mardasi</surname><given-names>M</given-names></name><name><surname>Sakhaei</surname><given-names>D</given-names></name><name><surname>Thangavelu</surname><given-names>L</given-names></name><name><surname>Shomali</surname><given-names>N</given-names></name><name><surname>Zamani</surname><given-names>M</given-names></name><name><surname>Mohammadi</surname><given-names>A</given-names></name><name><surname>Rahnama</surname><given-names>N</given-names></name></person-group><article-title>Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects</article-title><source>Cell Mol Biol Lett</source><year>2022</year><volume>27</volume><issue>1</issue><fpage>1</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1186/s11658-022-00359-z</pub-id><pub-id pub-id-type="pmid">34979906</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Panchalingam</surname><given-names>KM</given-names></name><name><surname>Assun&#x000e7;&#x000e3;o-Silva</surname><given-names>R</given-names></name><name><surname>Serra</surname><given-names>SC</given-names></name><name><surname>Mendes-Pinheiro</surname><given-names>B</given-names></name><name><surname>Patr&#x000ed;cio</surname><given-names>P</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Anjo</surname><given-names>SI</given-names></name><name><surname>Manadas</surname><given-names>B</given-names></name><name><surname>Pinto</surname><given-names>L</given-names></name><name><surname>Sousa</surname><given-names>N</given-names></name></person-group><article-title>Modulation of the mesenchymal stem cell secretome using computer-controlled bioreactors: impact on neuronal cell proliferation, survival and differentiation</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/srep27791</pub-id><pub-id pub-id-type="pmid">28442746</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Panchalingam</surname><given-names>KM</given-names></name><name><surname>Anjo</surname><given-names>SI</given-names></name><name><surname>Manadas</surname><given-names>B</given-names></name><name><surname>Pereira</surname><given-names>R</given-names></name><name><surname>Sousa</surname><given-names>N</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name><name><surname>Behie</surname><given-names>LA</given-names></name></person-group><article-title>Do hypoxia/normoxia culturing conditions change the neuroregulatory profile of Wharton Jelly mesenchymal stem cell secretome?</article-title><source>Stem Cell Res Therapy</source><year>2015</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1186/s13287-015-0124-z</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tse</surname><given-names>H-F</given-names></name><name><surname>Lian</surname><given-names>Q</given-names></name></person-group><article-title>Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives</article-title><source>Cell Transplant</source><year>2014</year><volume>23</volume><issue>9</issue><fpage>1045</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.3727/096368913X667709</pub-id><pub-id pub-id-type="pmid">23676629</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name></person-group><article-title>Quercetin combined with human umbilical cord Mesenchymal stem cells regulated tumour necrosis factor-&#x003b1;/interferon-&#x003b3;-stimulated peripheral blood mononuclear cells via activation of toll-like receptor 3 Signalling</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>499</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00499</pub-id><pub-id pub-id-type="pmid">32390844</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>YM</given-names></name><name><surname>Qiang</surname><given-names>LZ</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>MJ</given-names></name><name><surname>Wu</surname><given-names>HX</given-names></name></person-group><article-title>Mesenchymal stem cells alleviate liver injury induced by chronic-binge ethanol feeding in mice via release of TSG6 and suppression of STAT3 activation</article-title><source>Stem Cell Res Ther</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s13287-019-1547-8</pub-id><pub-id pub-id-type="pmid">31900237</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffi</surname><given-names>V</given-names></name><name><surname>Espinosa</surname><given-names>G</given-names></name><name><surname>Gajardo</surname><given-names>G</given-names></name><name><surname>Morales</surname><given-names>N</given-names></name><name><surname>Dur&#x000e1;n</surname><given-names>MC</given-names></name><name><surname>Uberti</surname><given-names>B</given-names></name></person-group><article-title>Pre-conditioning of equine bone marrow-derived mesenchymal stromal cells increases their immunomodulatory capacity</article-title><source>Front Vet Sci</source><year>2020</year><volume>7</volume><fpage>318</fpage><pub-id pub-id-type="doi">10.3389/fvets.2020.00318</pub-id><pub-id pub-id-type="pmid">32656251</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Carvalho</surname><given-names>MM</given-names></name><name><surname>Panchalingam</surname><given-names>KM</given-names></name><name><surname>Rodrigues</surname><given-names>AJ</given-names></name><name><surname>Mendes-Pinheiro</surname><given-names>B</given-names></name><name><surname>Anjo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of the secretome of human mesenchymal stem cells on brain structure and animal behavior in a rat model of Parkinson's disease</article-title><source>Stem Cells Transl Med</source><year>2017</year><volume>6</volume><issue>2</issue><fpage>634</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.5966/sctm.2016-0071</pub-id><pub-id pub-id-type="pmid">28191785</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whone</surname><given-names>AL</given-names></name><name><surname>Kemp</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Wilkins</surname><given-names>A</given-names></name><name><surname>Scolding</surname><given-names>NJ</given-names></name></person-group><article-title>Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor</article-title><source>Brain Res</source><year>2012</year><volume>1431</volume><fpage>86</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2011.10.038</pub-id><pub-id pub-id-type="pmid">22143094</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavigne</surname><given-names>EG</given-names></name><name><surname>Buttigieg</surname><given-names>D</given-names></name><name><surname>Steinschneider</surname><given-names>R</given-names></name><name><surname>Burstein</surname><given-names>ES</given-names></name></person-group><article-title>Pimavanserin promotes trophic factor release and protects cultured primary dopaminergic neurons exposed to MPP+ in a GDNF-dependent manner</article-title><source>ACS Chem Neurosci</source><year>2021</year><volume>12</volume><fpage>2088</fpage><lpage>2098</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.0c00751</pub-id><pub-id pub-id-type="pmid">34032411</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>LF</given-names></name><name><surname>Costa</surname><given-names>RO</given-names></name><name><surname>Pedro</surname><given-names>JR</given-names></name><name><surname>Aguiar</surname><given-names>P</given-names></name><name><surname>Serra</surname><given-names>SC</given-names></name><name><surname>Teixeira</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Mesenchymal stem cells secretome-induced axonal outgrowth is mediated by BDNF</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s41598-017-03592-1</pub-id><pub-id pub-id-type="pmid">28127051</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erskine</surname><given-names>L</given-names></name><name><surname>Reijntjes</surname><given-names>S</given-names></name><name><surname>Pratt</surname><given-names>T</given-names></name><name><surname>Denti</surname><given-names>L</given-names></name><name><surname>Schwarz</surname><given-names>Q</given-names></name><name><surname>Vieira</surname><given-names>JM</given-names></name><etal/></person-group><article-title>VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm</article-title><source>Neuron</source><year>2011</year><volume>70</volume><issue>5</issue><fpage>951</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.02.052</pub-id><pub-id pub-id-type="pmid">21658587</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Theis, Verena, and Carsten Theiss. Vascular endothelial growth factor and neurodevelopment. Factors Affecting Neurodevelopment. Academic Press; 2021;237&#x02013;46.</mixed-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Leong</surname><given-names>K</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Enhanced neuroprotective efficacy of bone marrow mesenchymal stem cells co-overexpressing BDNF and VEGF in a rat model of cardiac arrest-induced global cerebral ischemia</article-title><source>Cell Death Dis</source><year>2017</year><volume>8</volume><issue>5</issue><fpage>e2774</fpage><pub-id pub-id-type="doi">10.1038/cddis.2017.184</pub-id><pub-id pub-id-type="pmid">28492549</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dokic</surname><given-names>MJ</given-names></name><name><surname>Tomic</surname><given-names>ZS</given-names></name><name><surname>Colic</surname><given-names>JM</given-names></name></person-group><article-title>Cross-talk between mesenchymal stem/stromal cells and dendritic cells</article-title><source>Curr Stem Cell Res Ther</source><year>2016</year><volume>11</volume><issue>1</issue><fpage>51</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.2174/1574888X10666150904114035</pub-id><pub-id pub-id-type="pmid">26337378</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>E</given-names></name><name><surname>Son</surname><given-names>Y</given-names></name></person-group><article-title>Crosstalk between mesenchymal stem cells and macrophages in tissue repair</article-title><source>Tissue Eng Regener Med</source><year>2014</year><volume>11</volume><issue>6</issue><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1007/s13770-014-0072-1</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>MZ</given-names></name><name><surname>Yang</surname><given-names>ZY</given-names></name><name><surname>Jin</surname><given-names>WL</given-names></name></person-group><article-title>Microglia in neurodegenerative diseases</article-title><source>Neural Regener Res</source><year>2021</year><volume>16</volume><issue>2</issue><fpage>270</fpage><pub-id pub-id-type="doi">10.4103/1673-5374.290881</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name></person-group><article-title>Mesenchymal stem cells enhance microglia M2 polarization and attenuate neuroinflammation through TSG-6</article-title><source>Brain Res</source><year>2019</year><volume>1724</volume><fpage>146422</fpage><pub-id pub-id-type="doi">10.1016/j.brainres.2019.146422</pub-id><pub-id pub-id-type="pmid">31472111</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>Delivery of exogenous proteins by mesenchymal stem cells attenuates early memory deficits in a murine model of Alzheimer&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2020</year><volume>86</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.10.012</pub-id><pub-id pub-id-type="pmid">31837910</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>E</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name></person-group><article-title>Interferon-&#x003b3; mediates the immunosuppression of bone marrow mesenchymal stem cells on T-lymphocytes in vitro</article-title><source>Hematology</source><year>2018</year><volume>23</volume><issue>1</issue><fpage>44</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/10245332.2017.1333245</pub-id><pub-id pub-id-type="pmid">28581352</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magatti</surname><given-names>M</given-names></name><name><surname>Masserdotti</surname><given-names>A</given-names></name><name><surname>Bonassi Signoroni</surname><given-names>P</given-names></name><name><surname>Vertua</surname><given-names>E</given-names></name><name><surname>Stefani</surname><given-names>FR</given-names></name><name><surname>Silini</surname><given-names>AR</given-names></name></person-group><article-title>B Lymphocytes as targets of the immunomodulatory properties of human amniotic mesenchymal stromal cells</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>1156</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01156</pub-id><pub-id pub-id-type="pmid">32582218</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazdic</surname><given-names>M</given-names></name><name><surname>Volarevic</surname><given-names>V</given-names></name><name><surname>Arsenijevic</surname><given-names>N</given-names></name><name><surname>Stojkovic</surname><given-names>M</given-names></name></person-group><article-title>Mesenchymal stem cells: a friend or foe in immune-mediated diseases</article-title><source>Stem Cell Rev Rep</source><year>2015</year><volume>11</volume><issue>2</issue><fpage>280</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s12015-014-9583-3</pub-id><pub-id pub-id-type="pmid">25592610</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>JY</given-names></name><name><surname>Im</surname><given-names>KI</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Nam</surname><given-names>YS</given-names></name><name><surname>Jeon</surname><given-names>YW</given-names></name></person-group><article-title>Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/srep26851</pub-id><pub-id pub-id-type="pmid">28442746</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>N</given-names></name><name><surname>Scholtemeijer</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name></person-group><article-title>Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential</article-title><source>Trends Pharmacol Sci</source><year>2020</year><volume>41</volume><fpage>653</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2020.06.009</pub-id><pub-id pub-id-type="pmid">32709406</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnecchi</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>OD</given-names></name><name><surname>Melo</surname><given-names>LG</given-names></name><name><surname>Morello</surname><given-names>F</given-names></name><name><surname>Mu</surname><given-names>H</given-names></name></person-group><article-title>Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><issue>4</issue><fpage>367</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nm0405-367</pub-id><pub-id pub-id-type="pmid">15812508</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yahaya</surname><given-names>BH</given-names></name><name><surname>Ng</surname><given-names>WH</given-names></name><name><surname>Yusoff</surname><given-names>NM</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>Conditioned medium of human menstrual blood-derived endometrial stem cells protects against MPP+-induced cytotoxicity in vitro</article-title><source>Front Mol Neurosci</source><year>2019</year><volume>12</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2019.00080</pub-id><pub-id pub-id-type="pmid">31024252</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luarte</surname><given-names>A</given-names></name><name><surname>B&#x000e1;tiz</surname><given-names>LF</given-names></name><name><surname>Wyneken</surname><given-names>U</given-names></name><name><surname>Lafourcade</surname><given-names>C</given-names></name></person-group><article-title>Potential therapies by stem cell-derived exosomes in CNS diseases: focusing on the neurogenic niche</article-title><source>Stem Cells Int</source><year>2016</year><pub-id pub-id-type="doi">10.1155/2016/5736059</pub-id><pub-id pub-id-type="pmid">27195011</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Carvalho</surname><given-names>MM</given-names></name><name><surname>Neves-Carvalho</surname><given-names>A</given-names></name><name><surname>Panchalingam</surname><given-names>KM</given-names></name><name><surname>Behie</surname><given-names>LA</given-names></name><name><surname>Pinto</surname><given-names>L</given-names></name><etal/></person-group><article-title>Secretome of mesenchymal progenitors from the umbilical cord acts as modulator of neural/glial proliferation and differentiation</article-title><source>Stem Cell Rev Rep</source><year>2015</year><volume>11</volume><issue>2</issue><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1007/s12015-014-9576-2</pub-id><pub-id pub-id-type="pmid">25420577</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Kean</surname><given-names>T</given-names></name><name><surname>Young</surname><given-names>R</given-names></name><name><surname>Dennis</surname><given-names>JE</given-names></name><name><surname>Caplan</surname><given-names>AI</given-names></name></person-group><article-title>Optimizing mesenchymal stem cell-based therapeutics</article-title><source>Curr Opin Biotechnol</source><year>2009</year><volume>20</volume><issue>5</issue><fpage>531</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2009.08.009</pub-id><pub-id pub-id-type="pmid">19783424</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>AKL</given-names></name></person-group><article-title>Stem cell therapy for Alzheimer&#x02019;s disease: hype or hope?</article-title><source>Biosci Horiz Int J Stud Res</source><year>2013</year><pub-id pub-id-type="doi">10.1093/biohorizons/hzt011</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filadi</surname><given-names>R</given-names></name><name><surname>Pizzo</surname><given-names>P</given-names></name></person-group><article-title>Defective autophagy and Alzheimer&#x02019;s disease: is calcium the key?</article-title><source>Neural Regen Res</source><year>2019</year><volume>14</volume><issue>12</issue><fpage>2081</fpage><pub-id pub-id-type="doi">10.4103/1673-5374.262584</pub-id><pub-id pub-id-type="pmid">31397341</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botchway</surname><given-names>BOA</given-names></name><name><surname>Moore</surname><given-names>MK</given-names></name><name><surname>Akinleye</surname><given-names>FO</given-names></name><name><surname>Iyer</surname><given-names>IC</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name></person-group><article-title>Nutrition: review on the possible treatment for Alzheimer&#x02019;s disease</article-title><source>J Alzheimer&#x02019;s Dis</source><year>2018</year><volume>61</volume><issue>3</issue><fpage>867</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.3233/JAD-170874</pub-id><pub-id pub-id-type="pmid">29254101</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>MH</given-names></name><name><surname>Fatima</surname><given-names>M</given-names></name><name><surname>Mondal</surname><given-names>AC</given-names></name></person-group><article-title>Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimer&#x02019;s disease: rational insights for the therapeutic approaches</article-title><source>J Clin Neurosci</source><year>2019</year><volume>59</volume><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2018.10.034</pub-id><pub-id pub-id-type="pmid">30385170</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dansokho</surname><given-names>C</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name></person-group><article-title>Neuroinflammatory responses in Alzheimer&#x02019;s disease</article-title><source>J Neural Transm</source><year>2018</year><volume>125</volume><issue>5</issue><fpage>771</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00702-017-1831-7</pub-id><pub-id pub-id-type="pmid">29273951</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ries</surname><given-names>M</given-names></name><name><surname>Sastre</surname><given-names>M</given-names></name></person-group><article-title>Mechanisms of A&#x003b2; clearance and degradation by glial cells</article-title><source>Front Aging Neurosci</source><year>2016</year><volume>8</volume><fpage>160</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2016.00160</pub-id><pub-id pub-id-type="pmid">27458370</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glezer</surname><given-names>I</given-names></name><name><surname>Simard</surname><given-names>AR</given-names></name><name><surname>Rivest</surname><given-names>S</given-names></name></person-group><article-title>Neuroprotective role of the innate immune system by microglia</article-title><source>Neuroscience</source><year>2007</year><volume>147</volume><issue>4</issue><fpage>867</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.02.055</pub-id><pub-id pub-id-type="pmid">17459594</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>MM</given-names></name><name><surname>Hutchinson</surname><given-names>M</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name></person-group><article-title>Toll-like receptor 4 in CNS pathologies</article-title><source>J Neurochem</source><year>2010</year><volume>114</volume><issue>1</issue><fpage>13</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">20402965</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehrabadi</surname><given-names>S</given-names></name><name><surname>Motevaseli</surname><given-names>E</given-names></name><name><surname>Sadr</surname><given-names>SS</given-names></name><name><surname>Moradbeygi</surname><given-names>K</given-names></name></person-group><article-title>Hypoxic-conditioned medium from adipose tissue mesenchymal stem cells improved neuroinflammation through alternation of toll like receptor (TLR) 2 and TLR4 expression in model of Alzheimer&#x02019;s disease rats</article-title><source>Behav Brain Res</source><year>2020</year><volume>379</volume><fpage>112362</fpage><pub-id pub-id-type="doi">10.1016/j.bbr.2019.112362</pub-id><pub-id pub-id-type="pmid">31739000</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>D</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Deshmukh</surname><given-names>R</given-names></name></person-group><article-title>Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer&#x02019;s disease</article-title><source>Inflammopharmacology</source><year>2019</year><volume>27</volume><issue>4</issue><fpage>663</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/s10787-019-00580-x</pub-id><pub-id pub-id-type="pmid">30874945</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristiano</surname><given-names>C</given-names></name><name><surname>Volpicelli</surname><given-names>F</given-names></name><name><surname>Lippiello</surname><given-names>P</given-names></name><name><surname>Buono</surname><given-names>B</given-names></name><name><surname>Raucci</surname><given-names>F</given-names></name><name><surname>Piccolo</surname><given-names>M</given-names></name></person-group><article-title>Neutralization of IL-17 rescues amyloid-&#x003b2;-induced neuroinflammation and memory impairment</article-title><source>Br J Pharmacol</source><year>2019</year><volume>176</volume><issue>18</issue><fpage>3544</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/bph.14586</pub-id><pub-id pub-id-type="pmid">30673121</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barroeta-Espar</surname><given-names>I</given-names></name><name><surname>Weinstock</surname><given-names>LD</given-names></name><name><surname>Perez-Nievas</surname><given-names>BG</given-names></name><name><surname>Meltzer</surname><given-names>AC</given-names></name><name><surname>Chong</surname><given-names>MST</given-names></name><name><surname>Amaral</surname><given-names>AC</given-names></name></person-group><article-title>Distinct cytokine profiles in human brains resilient to Alzheimer&#x02019;s pathology</article-title><source>Neurobiol Dis</source><year>2019</year><volume>121</volume><fpage>327</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2018.10.009</pub-id><pub-id pub-id-type="pmid">30336198</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Bing</surname><given-names>ZH</given-names></name></person-group><article-title>Microglial polarization: novel therapeutic mechanism against Alzheimer&#x02019;s disease</article-title><source>Inflammopharmacology</source><year>2020</year><volume>28</volume><issue>1</issue><fpage>95</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1007/s10787-019-00613-5</pub-id><pub-id pub-id-type="pmid">31264132</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinuthia</surname><given-names>UM</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Langmann</surname><given-names>T</given-names></name></person-group><article-title>Microglia and inflammatory responses in diabetic retinopathy</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>564077</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.564077</pub-id><pub-id pub-id-type="pmid">33240260</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giunti</surname><given-names>D</given-names></name><name><surname>Parodi</surname><given-names>B</given-names></name><name><surname>Usai</surname><given-names>C</given-names></name><name><surname>Vergani</surname><given-names>L</given-names></name><name><surname>Casazza</surname><given-names>S</given-names></name><name><surname>Bruzzone</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1</article-title><source>Stem cells</source><year>2012</year><volume>30</volume><issue>9</issue><fpage>2044</fpage><lpage>2053</lpage><pub-id pub-id-type="doi">10.1002/stem.1174</pub-id><pub-id pub-id-type="pmid">22821677</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarty</surname><given-names>P</given-names></name><name><surname>Jansen-West</surname><given-names>K</given-names></name><name><surname>Beccard</surname><given-names>A</given-names></name><name><surname>Ceballos-Diaz</surname><given-names>C</given-names></name><name><surname>Levites</surname><given-names>Y</given-names></name><name><surname>Verbeeck</surname><given-names>C</given-names></name></person-group><article-title>Massive gliosis induced by interleukin-6 suppresses A&#x003b2; deposition in vivo: evidence against inflammation as a driving force for amyloid deposition</article-title><source>FASEB J</source><year>2010</year><volume>24</volume><issue>2</issue><fpage>548</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1096/fj.09-141754</pub-id><pub-id pub-id-type="pmid">19825975</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>XW</given-names></name><name><surname>Wang</surname><given-names>JZ</given-names></name></person-group><article-title>The dual roles of cytokines in Alzheimer&#x02019;s disease: update on interleukins, TNF-&#x003b1;, TGF-&#x003b2; and IFN-&#x003b3;</article-title><source>Transl Neurodegener</source><year>2016</year><volume>5</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1186/s40035-016-0054-4</pub-id><pub-id pub-id-type="pmid">26740872</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Ke</surname><given-names>KF</given-names></name><name><surname>Lu</surname><given-names>JH</given-names></name><name><surname>Qiu</surname><given-names>YH</given-names></name><name><surname>Peng</surname><given-names>YP</given-names></name></person-group><article-title>Protection of TGF-&#x003b2;1 against neuroinflammation and neurodegeneration in A&#x003b2;1&#x02013;42-induced Alzheimer&#x02019;s disease model rats</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>2</issue><fpage>e0116549</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0116549</pub-id><pub-id pub-id-type="pmid">25658940</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spooren</surname><given-names>A</given-names></name><name><surname>Kolmus</surname><given-names>K</given-names></name><name><surname>Laureys</surname><given-names>G</given-names></name><name><surname>Clinckers</surname><given-names>R</given-names></name><name><surname>Keyser</surname><given-names>J</given-names></name><name><surname>Haegeman</surname><given-names>G</given-names></name></person-group><article-title>Interleukin-6, a mental cytokine</article-title><source>Brain Res Rev</source><year>2011</year><volume>67</volume><issue>1&#x02013;2</issue><fpage>157</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.brainresrev.2011.01.002</pub-id><pub-id pub-id-type="pmid">21238488</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escrig</surname><given-names>A</given-names></name><name><surname>Canal</surname><given-names>C</given-names></name><name><surname>Sanchis</surname><given-names>P</given-names></name><name><surname>Fern&#x000e1;ndez-Gayol</surname><given-names>O</given-names></name><name><surname>Montilla</surname><given-names>A</given-names></name><name><surname>Comes</surname><given-names>G</given-names></name></person-group><article-title>IL-6 trans-signaling in the brain influences the behavioral and physio-pathological phenotype of the Tg2576 and 3xTgAD mouse models of Alzheimer&#x02019;s disease</article-title><source>Brain Behav Immun</source><year>2019</year><volume>82</volume><fpage>145</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2019.08.005</pub-id><pub-id pub-id-type="pmid">31401302</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Mesenchymal stem cells-derived IL-6 activates AMPK/mTOR signaling to inhibit the proliferation of reactive astrocytes induced by hypoxic-ischemic brain damage</article-title><source>Exp Neurol</source><year>2019</year><volume>311</volume><fpage>15</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2018.09.006</pub-id><pub-id pub-id-type="pmid">30213506</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Schuchman</surname><given-names>EH</given-names></name><name><surname>Jin</surname><given-names>HK</given-names></name><name><surname>Bae</surname><given-names>J</given-names></name></person-group><article-title>Soluble CCL5 derived from bone marrow-derived mesenchymal stem cells and activated by amyloid &#x003b2; ameliorates Alzheimer&#x02019;s disease in mice by recruiting bone marrow-induced microglia immune responses</article-title><source>Stem Cells</source><year>2012</year><volume>30</volume><issue>7</issue><fpage>1544</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1002/stem.1125</pub-id><pub-id pub-id-type="pmid">22570192</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>RH</given-names></name><name><surname>Qi</surname><given-names>RQ</given-names></name><name><surname>Liu</surname><given-names>HY</given-names></name></person-group><article-title>Interleukin-4 affects microglial autophagic flux</article-title><source>Neural Regen Res</source><year>2019</year><volume>14</volume><issue>9</issue><fpage>1594</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.255975</pub-id><pub-id pub-id-type="pmid">31089059</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>MG</given-names></name><name><surname>Liu</surname><given-names>CF</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>WB</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Hai</surname><given-names>H</given-names></name></person-group><article-title>MiR-21 attenuates apoptosis-triggered by amyloid-&#x003b2; via modulating PDCD4/PI3K/AKT/GSK-3&#x003b2; pathway in SH-SY5Y cells</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>101</volume><fpage>1003</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.02.043</pub-id><pub-id pub-id-type="pmid">29635890</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanamaru</surname><given-names>T</given-names></name><name><surname>Kamimura</surname><given-names>N</given-names></name><name><surname>Yokota</surname><given-names>T</given-names></name><name><surname>Iuchi</surname><given-names>K</given-names></name><name><surname>Nishimaki</surname><given-names>K</given-names></name><name><surname>Takami</surname><given-names>S</given-names></name></person-group><article-title>Oxidative stress accelerates amyloid deposition and memory impairment in a double-transgenic mouse model of Alzheimer&#x02019;s disease</article-title><source>Neurosci Lett</source><year>2015</year><volume>587</volume><fpage>126</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2014.12.033</pub-id><pub-id pub-id-type="pmid">25529196</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Baranzini</surname><given-names>SE</given-names></name><name><surname>Geurts</surname><given-names>J</given-names></name><name><surname>Hemmer</surname><given-names>B</given-names></name><name><surname>Ciccarelli</surname><given-names>O</given-names></name></person-group><article-title>Multiple sclerosis</article-title><source>Lancet Lond Engl</source><year>2018</year><volume>391</volume><fpage>1622</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)30481-1</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwanowski</surname><given-names>P</given-names></name><name><surname>Losy</surname><given-names>J</given-names></name></person-group><article-title>Immunological differences between classical phenothypes of multiple sclerosis</article-title><source>J Neurol Sci</source><year>2015</year><volume>349</volume><issue>1&#x02013;2</issue><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2014.12.035</pub-id><pub-id pub-id-type="pmid">25586536</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ontaneda</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Fox</surname><given-names>RJ</given-names></name><name><surname>Cohen</surname><given-names>JA</given-names></name></person-group><article-title>Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function</article-title><source>Lancet</source><year>2017</year><volume>389</volume><issue>10076</issue><fpage>1357</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31320-4</pub-id><pub-id pub-id-type="pmid">27889191</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baecher-Allan</surname><given-names>C</given-names></name><name><surname>Kaskow</surname><given-names>BJ</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name></person-group><article-title>Multiple sclerosis: mechanisms and immunotherapy</article-title><source>Neuron</source><year>2018</year><volume>97</volume><issue>4</issue><fpage>742</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.01.021</pub-id><pub-id pub-id-type="pmid">29470968</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><mixed-citation publication-type="other">Wagner CA, Roqu&#x000e9; PJ, Goverman JM. Pathogenic T cell cytokines in multiple sclerosis. J Exp Med. 2020;217(1).</mixed-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J-F</given-names></name><name><surname>Zhang</surname><given-names>D-J</given-names></name><name><surname>Geng</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Yin</surname><given-names>H-L</given-names></name><etal/></person-group><article-title>The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis</article-title><source>Cell Transplant</source><year>2014</year><volume>23</volume><fpage>113</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3727/096368914X685005</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobaeus</surname><given-names>E</given-names></name><name><surname>Kadri</surname><given-names>N</given-names></name><name><surname>Lefsihane</surname><given-names>K</given-names></name><name><surname>Boberg</surname><given-names>E</given-names></name><name><surname>Gavin</surname><given-names>C</given-names></name><name><surname>T&#x000f6;rnqvist Andr&#x000e9;n</surname><given-names>A</given-names></name><etal/></person-group><article-title>Short and long term clinical and immunologic follow up after bone marrow mesenchymal stromal cell therapy in progressive multiple sclerosis&#x02014;a phase i study</article-title><source>J Clin Medi</source><year>2019</year><volume>8</volume><issue>12</issue><fpage>2102</fpage><pub-id pub-id-type="doi">10.3390/jcm8122102</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>TW</given-names></name></person-group><article-title>An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis</article-title><source>Brain Behav.</source><year>2015</year><volume>5</volume><issue>9</issue><fpage>e00362</fpage><pub-id pub-id-type="doi">10.1002/brb3.362</pub-id><pub-id pub-id-type="pmid">26445701</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>RCH</given-names></name></person-group><article-title>Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion</article-title><source>Exp Hematol</source><year>2012</year><volume>40</volume><issue>9</issue><fpage>761</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2012.05.006</pub-id><pub-id pub-id-type="pmid">22634392</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>W-X</given-names></name><name><surname>Sun</surname><given-names>Y-Q</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C-L</given-names></name><name><surname>Fang</surname><given-names>S-B</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of mesenchymal stem cells from human induced pluripotent stem cells on differentiation, maturation, and function of dendritic cells</article-title><source>Stem Cell Res Ther</source><year>2017</year><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/s13287-017-0499-0</pub-id><pub-id pub-id-type="pmid">28057078</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000fc;bel</surname><given-names>J</given-names></name><name><surname>Hieronymus</surname><given-names>T</given-names></name></person-group><article-title>HGF/Met-signaling contributes to immune regulation by modulating tolerogenic and motogenic properties of dendritic cells</article-title><source>Biomedicines</source><year>2015</year><volume>3</volume><issue>1</issue><fpage>138</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.3390/biomedicines3010138</pub-id><pub-id pub-id-type="pmid">28536404</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Lennon</surname><given-names>DP</given-names></name><name><surname>Caplan</surname><given-names>AI</given-names></name><name><surname>DeChant</surname><given-names>A</given-names></name><name><surname>Hecker</surname><given-names>J</given-names></name><name><surname>Kranso</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hepatocyte growth factor mediates mesenchymal stem cell&#x02013;induced recovery in multiple sclerosis models</article-title><source>Nat Neurosci</source><year>2012</year><volume>15</volume><issue>6</issue><fpage>862</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1038/nn.3109</pub-id><pub-id pub-id-type="pmid">22610068</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maseda</surname><given-names>D</given-names></name><name><surname>Ricciotti</surname><given-names>E</given-names></name><name><surname>Crofford</surname><given-names>LJ</given-names></name></person-group><article-title>Prostaglandin regulation of T cell biology</article-title><source>Pharmacol Res</source><year>2019</year><volume>149</volume><fpage>104456</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104456</pub-id><pub-id pub-id-type="pmid">31553935</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boniface</surname><given-names>K</given-names></name><name><surname>Bak-Jensen</surname><given-names>KS</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Blumenschein</surname><given-names>WM</given-names></name><name><surname>McGeachy</surname><given-names>MJ</given-names></name><name><surname>McClanahan</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling</article-title><source>J Exp Med</source><year>2009</year><volume>206</volume><issue>3</issue><fpage>535</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1084/jem.20082293</pub-id><pub-id pub-id-type="pmid">19273625</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Seeburg</surname><given-names>DP</given-names></name><name><surname>Wojtkiewicz</surname><given-names>GR</given-names></name><name><surname>Waterman</surname><given-names>P</given-names></name><name><surname>Pulli</surname><given-names>B</given-names></name><etal/></person-group><article-title>Multimodal molecular imaging demonstrates myeloperoxidase regulation of matrix metalloproteinase activity in neuroinflammation</article-title><source>Mol Neurobiol</source><year>2019</year><volume>56</volume><issue>2</issue><fpage>954</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1007/s12035-018-1137-2</pub-id><pub-id pub-id-type="pmid">29808380</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chelluboina</surname><given-names>B</given-names></name><name><surname>Nalamolu</surname><given-names>KR</given-names></name><name><surname>Mendez</surname><given-names>GG</given-names></name><name><surname>Klopfenstein</surname><given-names>JD</given-names></name><name><surname>Pinson</surname><given-names>DM</given-names></name><name><surname>Wang</surname><given-names>DZ</given-names></name><etal/></person-group><article-title>Mesenchymal stem cell treatment prevents post-stroke dysregulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases</article-title><source>Cell Physiol Biochem</source><year>2017</year><volume>44</volume><issue>4</issue><fpage>1360</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1159/000485533</pub-id><pub-id pub-id-type="pmid">29186705</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>AG</given-names></name><name><surname>Long</surname><given-names>G</given-names></name><name><surname>Tyler</surname><given-names>G</given-names></name><name><surname>Stefan</surname><given-names>A</given-names></name><name><surname>Broadfoot</surname><given-names>SJ</given-names></name><name><surname>Piccinini</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Mesenchymal stem cell-conditioned medium reduces disease severity and immune responses in inflammatory arthritis</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41598-017-18144-w</pub-id><pub-id pub-id-type="pmid">28127051</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozito</surname><given-names>TP</given-names></name><name><surname>Tuan</surname><given-names>RS</given-names></name></person-group><article-title>Mesenchymal stem cells inhibit both endogenous and exogenous MMPs via secreted TIMPs</article-title><source>J Cell Physiol</source><year>2011</year><volume>226</volume><issue>2</issue><fpage>385</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1002/jcp.22344</pub-id><pub-id pub-id-type="pmid">20665704</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype</article-title><source>Cell Death Dis</source><year>2020</year><volume>11</volume><issue>5</issue><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/s41419-020-2565-2</pub-id><pub-id pub-id-type="pmid">31911576</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soundara Rajan</surname><given-names>T</given-names></name><name><surname>Giacoppo</surname><given-names>S</given-names></name><name><surname>Diomede</surname><given-names>F</given-names></name><name><surname>Bramanti</surname><given-names>P</given-names></name><name><surname>Trubiani</surname><given-names>O</given-names></name><name><surname>Mazzon</surname><given-names>E</given-names></name></person-group><article-title>Human periodontal ligament stem cells secretome from multiple sclerosis patients suppresses NALP3 inflammasome activation in experimental autoimmune encephalomyelitis</article-title><source>Int J Immunopathol Pharmacol</source><year>2017</year><volume>30</volume><issue>3</issue><fpage>238</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1177/0394632017722332</pub-id><pub-id pub-id-type="pmid">28764573</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurung</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Malireddi</surname><given-names>RKS</given-names></name><name><surname>Lamkanfi</surname><given-names>M</given-names></name><name><surname>Geiger</surname><given-names>TL</given-names></name><name><surname>Kanneganti</surname><given-names>T-D</given-names></name></person-group><article-title>Chronic TLR stimulation controls NLRP3 inflammasome activation through IL-10 mediated regulation of NLRP3 expression and caspase-8 activation</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/srep14488</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karmand</surname><given-names>Z</given-names></name><name><surname>Hartung</surname><given-names>HP</given-names></name><name><surname>Neuhaus</surname><given-names>O</given-names></name></person-group><article-title>Interferon beta-1a induces expression of brain-derived neurotrophic factor in human T lymphocytes in vitro and not in vivo</article-title><source>Future Neurol</source><year>2020</year><volume>15</volume><issue>1</issue><fpage>FNL38</fpage><pub-id pub-id-type="doi">10.2217/fnl-2019-0018</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banitalebi</surname><given-names>E</given-names></name><name><surname>Ghahfarrokhi</surname><given-names>MM</given-names></name><name><surname>Negaresh</surname><given-names>R</given-names></name><name><surname>Kazemi</surname><given-names>A</given-names></name><name><surname>Faramarzi</surname><given-names>M</given-names></name><name><surname>Motl</surname><given-names>RW</given-names></name></person-group><article-title>Exercise improves neurotrophins in multiple sclerosis independent of disability status</article-title><source>Mult Scler Related Disord</source><year>2020</year><volume>43</volume><fpage>102143</fpage><pub-id pub-id-type="doi">10.1016/j.msard.2020.102143</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalash</surname><given-names>AS</given-names></name><name><surname>Hamid</surname><given-names>E</given-names></name><name><surname>Elrassas</surname><given-names>HH</given-names></name><name><surname>Bedair</surname><given-names>AS</given-names></name><name><surname>Abushouk</surname><given-names>AI</given-names></name><name><surname>Khamis</surname><given-names>M</given-names></name></person-group><article-title>Non-motor symptoms as predictors of quality of life in Egyptian patients with Parkinson&#x02019;s disease: a cross-sectional study using a culturally adapted 39-item Parkinson&#x02019;s disease questionnaire</article-title><source>Front Neurol</source><year>2018</year><volume>9</volume><fpage>357</fpage><pub-id pub-id-type="doi">10.3389/fneur.2018.00357</pub-id><pub-id pub-id-type="pmid">29881368</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manne</surname><given-names>S</given-names></name><name><surname>Kondru</surname><given-names>N</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Anantharam</surname><given-names>V</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Kanthasamy</surname><given-names>A</given-names></name></person-group><article-title>&#x003b1;-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson&#x02019;s disease patients</article-title><source>Mov Disord</source><year>2020</year><volume>35</volume><issue>2</issue><fpage>268</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/mds.27907</pub-id><pub-id pub-id-type="pmid">31758740</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sveinbjornsdottir</surname><given-names>S</given-names></name></person-group><article-title>The clinical symptoms of Parkinson&#x02019;s disease</article-title><source>J Neurochem</source><year>2016</year><volume>139</volume><fpage>318</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1111/jnc.13691</pub-id><pub-id pub-id-type="pmid">27401947</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>T</given-names></name><name><surname>Pu</surname><given-names>J</given-names></name><name><surname>Si</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>An update on potential therapeutic strategies for Parkinson&#x02019;s disease based on pathogenic mechanisms</article-title><source>Expert Rev Neurother</source><year>2016</year><volume>16</volume><issue>6</issue><fpage>711</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1080/14737175.2016.1179112</pub-id><pub-id pub-id-type="pmid">27138872</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Englund</surname><given-names>E</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Soulet</surname><given-names>D</given-names></name><name><surname>Hagell</surname><given-names>P</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>Lewy bodies in grafted neurons in subjects with Parkinson&#x02019;s disease suggest host-to-graft disease propagation</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><issue>5</issue><fpage>501</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/nm1746</pub-id><pub-id pub-id-type="pmid">18391963</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkataramana</surname><given-names>NK</given-names></name><name><surname>Kumar</surname><given-names>SK</given-names></name><name><surname>Balaraju</surname><given-names>S</given-names></name><name><surname>Radhakrishnan</surname><given-names>RC</given-names></name><name><surname>Bansal</surname><given-names>A</given-names></name><name><surname>Dixit</surname><given-names>A</given-names></name><etal/></person-group><article-title>Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson&#x02019;s disease</article-title><source>Transl Res</source><year>2010</year><volume>155</volume><issue>2</issue><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2009.07.006</pub-id><pub-id pub-id-type="pmid">20129486</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakane</surname><given-names>F</given-names></name><name><surname>Miyamoto</surname><given-names>Y</given-names></name></person-group><article-title>N-cadherin regulates the proliferation and differentiation of ventral midbrain dopaminergic progenitors</article-title><source>Dev Neurobiol</source><year>2013</year><volume>73</volume><issue>7</issue><fpage>518</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1002/dneu.22077</pub-id><pub-id pub-id-type="pmid">23420609</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Vila&#x000e7;a-Faria</surname><given-names>H</given-names></name><name><surname>Domingues</surname><given-names>AV</given-names></name><name><surname>Campos</surname><given-names>J</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name></person-group><article-title>Preclinical comparison of stem cells secretome and levodopa application in a 6-hydroxydopamine rat model of Parkinson&#x02019;s disease</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>2</issue><fpage>315</fpage><pub-id pub-id-type="doi">10.3390/cells9020315</pub-id><pub-id pub-id-type="pmid">32012897</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerri</surname><given-names>S</given-names></name><name><surname>Greco</surname><given-names>R</given-names></name><name><surname>Levandis</surname><given-names>G</given-names></name><name><surname>Ghezzi</surname><given-names>C</given-names></name><name><surname>Mangione</surname><given-names>AS</given-names></name><name><surname>Fuzzati-Armentero</surname><given-names>MT</given-names></name></person-group><article-title>Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson&#x02019;s disease, focusing on cell distribution and neuroprotective and behavioral effects</article-title><source>Stem Cells Transl Med</source><year>2015</year><volume>4</volume><issue>9</issue><fpage>1073</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.5966/sctm.2015-0023</pub-id><pub-id pub-id-type="pmid">26198165</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baquet</surname><given-names>ZC</given-names></name><name><surname>Bickford</surname><given-names>PC</given-names></name><name><surname>Jones</surname><given-names>KR</given-names></name></person-group><article-title>Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><issue>26</issue><fpage>6251</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4601-04.2005</pub-id><pub-id pub-id-type="pmid">15987955</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>zhang</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effects of salvianolic acid B on survival, self-renewal and neuronal differentiation of bone marrow derived neural stem cells.</article-title><source>Eur. J. Pharmacol.</source><year>2012</year><volume>697</volume><issue>2</issue><fpage>32-39</fpage><pub-id pub-id-type="pmid">23085027</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Nie</surname><given-names>Z</given-names></name><name><surname>Shu</surname><given-names>H</given-names></name><name><surname>Kuang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name></person-group><article-title>The role of BDNF on neural plasticity in depression</article-title><source>Front Cell Neurosci</source><year>2020</year><volume>14</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.3389/fncel.2020.00082</pub-id><pub-id pub-id-type="pmid">32351365</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Qiao</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>FM</given-names></name></person-group><article-title>Exercise-induced neuroprotection of the nigrostriatal dopamine system in Parkinson&#x02019;s disease</article-title><source>Front Aging Neurosci</source><year>2017</year><volume>9</volume><fpage>358</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2017.00358</pub-id><pub-id pub-id-type="pmid">29163139</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Beejadhursing</surname><given-names>R</given-names></name></person-group><article-title>GDNF promotes survival and therapeutic efficacy of human adipose-derived mesenchymal stem cells in a mouse model of Parkinson&#x02019;s disease</article-title><source>Cell Transplant</source><year>2020</year><volume>29</volume><fpage>0963689720908512</fpage><pub-id pub-id-type="doi">10.1177/0963689720908512</pub-id><pub-id pub-id-type="pmid">32292068</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>JP</given-names></name><name><surname>Niu</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><name><surname>Huang</surname><given-names>XG</given-names></name><name><surname>Gao</surname><given-names>DS</given-names></name></person-group><article-title>NF-&#x003ba;B p65/p52 plays a role in GDNF up-regulating Bcl-2 and Bcl-w expression in 6-OHDA-induced apoptosis of MN9D cell</article-title><source>Int J Neurosci</source><year>2013</year><volume>123</volume><issue>10</issue><fpage>705</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3109/00207454.2013.795149</pub-id><pub-id pub-id-type="pmid">23590664</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>EHY</given-names></name></person-group><article-title>Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: role of antioxidation</article-title><source>Neuropharmacology</source><year>1999</year><volume>38</volume><issue>6</issue><fpage>913</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(99)00030-1</pub-id><pub-id pub-id-type="pmid">10465695</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erta</surname><given-names>M</given-names></name><name><surname>Quintana</surname><given-names>A</given-names></name><name><surname>Hidalgo</surname><given-names>J</given-names></name></person-group><article-title>Interleukin-6, a major cytokine in the central nervous system</article-title><source>Int J Biol Sci</source><year>2012</year><volume>8</volume><issue>9</issue><fpage>1254</fpage><pub-id pub-id-type="doi">10.7150/ijbs.4679</pub-id><pub-id pub-id-type="pmid">23136554</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akaneya</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Hatanaka</surname><given-names>H</given-names></name></person-group><article-title>Interleukin-1&#x003b2; enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons</article-title><source>Exp Neurol</source><year>1995</year><volume>136</volume><issue>1</issue><fpage>44</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1006/exnr.1995.1082</pub-id><pub-id pub-id-type="pmid">7589333</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolin</surname><given-names>LM</given-names></name><name><surname>Strycharska-Orczyk</surname><given-names>I</given-names></name><name><surname>Murray</surname><given-names>R</given-names></name><name><surname>Langston</surname><given-names>JW</given-names></name><name><surname>Monte</surname><given-names>D</given-names></name></person-group><article-title>Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice</article-title><source>J Neurochem</source><year>2002</year><volume>83</volume><issue>1</issue><fpage>167</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.01131.x</pub-id><pub-id pub-id-type="pmid">12358740</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palasz</surname><given-names>E</given-names></name><name><surname>Wysocka</surname><given-names>A</given-names></name><name><surname>Gasiorowska</surname><given-names>A</given-names></name><name><surname>Chalimoniuk</surname><given-names>M</given-names></name><name><surname>Niewiadomski</surname><given-names>W</given-names></name><name><surname>Niewiadomska</surname><given-names>G</given-names></name></person-group><article-title>BDNF as a promising therapeutic agent in Parkinson&#x02019;s disease</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>3</issue><fpage>1170</fpage><pub-id pub-id-type="doi">10.3390/ijms21031170</pub-id><pub-id pub-id-type="pmid">32050617</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casper</surname><given-names>D</given-names></name><name><surname>Blum</surname><given-names>M</given-names></name></person-group><article-title>Epidermal growth factor and basic fibroblast growth factor protect dopaminergic neurons from glutamate toxicity in culture</article-title><source>J Neurochem</source><year>1995</year><volume>65</volume><issue>3</issue><fpage>1016</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1995.65031016.x</pub-id><pub-id pub-id-type="pmid">7643081</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Fukuda-Tani</surname><given-names>M</given-names></name><name><surname>Nihira</surname><given-names>T</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name></person-group><article-title>Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson&#x02019;s disease</article-title><source>Exp Neurol</source><year>2007</year><volume>206</volume><issue>2</issue><fpage>308</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2007.05.012</pub-id><pub-id pub-id-type="pmid">17604022</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>H</given-names></name></person-group><article-title>Vascular endothelial growth factor-loaded poly-lactic-co-glycolic acid nanoparticles with controlled release protect the dopaminergic neurons in Parkinson&#x02019;s rats</article-title><source>Chem Biol Drug Des</source><year>2020</year><volume>95</volume><issue>6</issue><fpage>631</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/cbdd.13681</pub-id><pub-id pub-id-type="pmid">32167672</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falk</surname><given-names>T</given-names></name><name><surname>Gonzalez</surname><given-names>RT</given-names></name><name><surname>Sherman</surname><given-names>SJ</given-names></name></person-group><article-title>The Yin and Yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson&#x02019;s disease</article-title><source>Int J Mol Sci</source><year>2010</year><volume>11</volume><issue>8</issue><fpage>2875</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.3390/ijms11082875</pub-id><pub-id pub-id-type="pmid">21152280</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendes-Pinheiro</surname><given-names>B</given-names></name><name><surname>Anjo</surname><given-names>SI</given-names></name><name><surname>Manadas</surname><given-names>B</given-names></name><name><surname>Silva</surname><given-names>JD</given-names></name><name><surname>Marote</surname><given-names>A</given-names></name><name><surname>Behie</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Bone marrow mesenchymal stem cells&#x02019; secretome exerts neuroprotective efects in a Parkinson&#x02019;s disease rat model</article-title><source>Front Bioeng Biotechnol</source><year>2019</year><volume>7</volume><fpage>294</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2019.00294</pub-id><pub-id pub-id-type="pmid">31737616</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Gong</surname><given-names>K</given-names></name><name><surname>Ao</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Adipose-derived mesenchymal stem cell transplantation promotes adult neurogenesis in the brains of Alzheimer&#x02019;s disease mice</article-title><source>Neural Regener Res.</source><year>2014</year><volume>9</volume><issue>8</issue><fpage>798</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.131596</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>E</given-names></name><etal/></person-group><article-title>GDF-15 secreted from human umbilical cord blood mesenchymal stem cells delivered through the cerebrospinal fluid promotes hippocampal neurogenesis and synaptic activity in an Alzheimer's disease model</article-title><source>Stem Cells Develop.</source><year>2015</year><volume>24</volume><issue>20</issue><fpage>2378</fpage><lpage>2390</lpage><pub-id pub-id-type="doi">10.1089/scd.2014.0487</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><mixed-citation publication-type="other">Xie ZH, Liu Z, Zhang XR, Yang H, Wei LF, Wang Y, Xu SL, Sun L, Lai C, Bi JZ, Wang XY. Wharton's Jelly-derived mesenchymal stem cells alleviate memory deficits and reduce amyloid-&#x003b2; deposition in an APP/PS1 transgenic mouse model. Clin Exp Med. 2016, 16(1),89&#x02013;98. <pub-id pub-id-type="doi">10.1007/s10238-015-0375-0</pub-id></mixed-citation></ref><ref id="CR155"><label>155.</label><mixed-citation publication-type="other">Nakano, M., Kubota, K., Kobayashi, E. et al. Bone marrow-derived mesenchymal stem cells improve cognitive impairment in an Alzheimer&#x02019;s disease model by increasing the expression of microRNA-146a in hippocampus. Sci Rep 10:10772</mixed-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SE</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>EH</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Sung</surname><given-names>JH</given-names></name><name><surname>Na</surname><given-names>DL</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name></person-group><article-title>Activin A secreted by human mesenchymal stem cells induces neuronal development and neurite outgrowth in an in vitro model of Alzheimer's disease: neurogenesis induced by MSCs via activin A</article-title><source>Arch Pharm Res.</source><year>2016</year><volume>39</volume><issue>8</issue><fpage>1171</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s12272-016-0799-4</pub-id><pub-id pub-id-type="pmid">27515053</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>NK</given-names></name><name><surname>Park</surname><given-names>SE</given-names></name><name><surname>Kwon</surname><given-names>SJ</given-names></name><name><surname>Shim</surname><given-names>S</given-names></name><name><surname>Byeon</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Na</surname><given-names>DL</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name></person-group><article-title>Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer's Disease Model</article-title><source>Sci Rep.</source><year>2017</year><volume>7</volume><fpage>39340</fpage><pub-id pub-id-type="doi">10.1038/srep39340</pub-id><pub-id pub-id-type="pmid">28051110</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>XY</given-names></name><name><surname>Wan</surname><given-names>QQ</given-names></name><name><surname>Zheng</surname><given-names>CY</given-names></name><name><surname>Zhou</surname><given-names>HL</given-names></name><name><surname>Dong</surname><given-names>XY</given-names></name><name><surname>Deng</surname><given-names>QS</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>ZJ</given-names></name><name><surname>Wang</surname><given-names>SS</given-names></name><name><surname>You</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Chen</surname><given-names>KE</given-names></name><name><surname>Zhang</surname><given-names>MY</given-names></name><name><surname>Xu</surname><given-names>RX</given-names></name></person-group><article-title>Amniotic Mesenchymal Stem Cells Decrease A&#x003b2; Deposition and Improve Memory in APP/PS1 Transgenic Mice</article-title><source>Neurochem Res.</source><year>2017</year><volume>42</volume><issue>8</issue><fpage>2191</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1007/s11064-017-2226-8</pub-id><pub-id pub-id-type="pmid">28397068</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naaldijk</surname><given-names>Y</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>C</given-names></name><name><surname>Fabian</surname><given-names>C</given-names></name><name><surname>Leovsky</surname><given-names>C</given-names></name><name><surname>Bl&#x000fc;her</surname><given-names>A</given-names></name><name><surname>Rudolph</surname><given-names>L</given-names></name><name><surname>Hinze</surname><given-names>A</given-names></name><name><surname>Stolzing</surname><given-names>A</given-names></name></person-group><article-title>Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice</article-title><source>Neuropathol Appl Neurobiol.</source><year>2017</year><volume>43</volume><issue>4</issue><fpage>299</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1111/nan.12319</pub-id><pub-id pub-id-type="pmid">26918424</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Lim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Oh</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>YS</given-names></name><name><surname>Oh</surname><given-names>JS</given-names></name><name><surname>Hwang</surname><given-names>HH</given-names></name><name><surname>Jeon</surname><given-names>HB</given-names></name></person-group><article-title>Thrombospondin-1 secreted by human umbilical cord blood-derived mesenchymal stem cells rescues neurons from synaptic dysfunction in Alzheimer's disease model</article-title><source>Sci Rep.</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>354</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-18542-0</pub-id><pub-id pub-id-type="pmid">29321508</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>C</given-names></name></person-group><article-title>Transplantation of Human Menstrual Blood-Derived Mesenchymal Stem Cells Alleviates Alzheimer's Disease-Like Pathology in APP/PS1 Transgenic Mice</article-title><source>Front Mol Neurosci.</source><year>2018</year><volume>11</volume><fpage>140</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2018.00140</pub-id><pub-id pub-id-type="pmid">29740283</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>BN</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lim</surname><given-names>TS</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>TG</given-names></name><name><surname>Yoon</surname><given-names>BS</given-names></name><name><surname>Son</surname><given-names>KS</given-names></name><name><surname>Yoon</surname><given-names>JK</given-names></name><name><surname>An</surname><given-names>YS</given-names></name></person-group><article-title>Therapeutic effect of mesenchymal stem cells in an animal model of Alzheimer's disease evaluated by &#x003b2;-amyloid positron emission tomography imaging</article-title><source>Aust N Z J Psychiatry.</source><year>2020</year><volume>54</volume><issue>9</issue><fpage>883</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1177/0004867420917467</pub-id><pub-id pub-id-type="pmid">32436738</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Choi</surname><given-names>W</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Oh</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name></person-group><article-title>Galectin-3 secreted by human umbilical cord blood-derived mesenchymal stem cells reduces aberrant tau phosphorylation in an Alzheimer disease model</article-title><source>Stem Cells Int.</source><year>2020</year><volume>2020</volume><fpage>8878412</fpage><pub-id pub-id-type="doi">10.1155/2020/8878412</pub-id><pub-id pub-id-type="pmid">32733573</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>M</given-names></name><name><surname>Kubota</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Bone marrow-derived mesenchymal stem cells improve cognitive impairment in an Alzheimer&#x02019;s disease model by increasing the expression of microRNA-146a in hippocampus</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>10772</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-67460-1</pub-id><pub-id pub-id-type="pmid">32612165</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santamaria</surname><given-names>G</given-names></name><name><surname>Brandi</surname><given-names>E</given-names></name><name><surname>Vitola</surname><given-names>P</given-names></name><name><surname>Grandi</surname><given-names>F</given-names></name><name><surname>Ferrara</surname><given-names>G</given-names></name><name><surname>Pischiutta</surname><given-names>F</given-names></name><name><surname>Vegliante</surname><given-names>G</given-names></name><name><surname>Zanier</surname><given-names>ER</given-names></name><name><surname>Re</surname><given-names>F</given-names></name><name><surname>Uccelli</surname><given-names>A</given-names></name><name><surname>Forloni</surname><given-names>G</given-names></name><name><surname>de Rosbo</surname><given-names>NK</given-names></name><name><surname>Balducci</surname><given-names>C</given-names></name></person-group><article-title>Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice</article-title><source>Cell Death Differ.</source><year>2021</year><volume>28</volume><issue>1</issue><fpage>203</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-0592-2</pub-id><pub-id pub-id-type="pmid">32704089</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><mixed-citation publication-type="other">Park, Kim H, Kwon S, et al. Exposure of mesenchymal stem cells to an Alzheimer&#x02019;s disease environment enhances 10 Stem Cells Internationaltherapeutic effects. Stem Cells Int. 2021;2021:6660186.</mixed-citation></ref><ref id="CR167"><label>167.</label><mixed-citation publication-type="other">Kurte M, Bravo-Alegria J, Torres A, Carrasco V, Ibanez C, Vega-Letter AM, Fernandez-O&#x02019;Ryan C, Irarrazabal CE, Figueroa FE, Fuentealba RA, et al. Intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis. Stem Cells Int. 2015;2015:140170.</mixed-citation></ref><ref id="CR168"><label>168.</label><mixed-citation publication-type="other">Glenn JD, Smith MD, Kirby LA, Baxi EG, Whartenby KA. Disparate Effects of Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis and Cuprizone-Induced Demyelination. PLoS One. 2015;10(9).</mixed-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Akabawy</surname><given-names>G</given-names></name><name><surname>Rashed</surname><given-names>LA</given-names></name></person-group><article-title>Beneficial effects of bone marrow-derived mesenchymal stem cell transplantation in a non-immune model of demyelination</article-title><source>Ann Anat.</source><year>2015</year><volume>198</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.aanat.2014.12.002</pub-id><pub-id pub-id-type="pmid">25660362</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>P</given-names></name><name><surname>Gonzalez-Rey</surname><given-names>E</given-names></name><name><surname>O&#x02019;Valle</surname><given-names>F</given-names></name><name><surname>Martin</surname><given-names>F</given-names></name><name><surname>Oliver</surname><given-names>FJ</given-names></name><name><surname>Delgado</surname><given-names>M</given-names></name></person-group><article-title>Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function</article-title><source>Stem Cells Int.</source><year>2017</year><volume>2017</volume><fpage>2389753</fpage><pub-id pub-id-type="doi">10.1155/2017/2389753</pub-id><pub-id pub-id-type="pmid">28250776</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahfouz</surname><given-names>MM</given-names></name><name><surname>Abdelsalam</surname><given-names>RM</given-names></name><name><surname>Masoud</surname><given-names>MA</given-names></name><name><surname>Mansour</surname><given-names>HA</given-names></name><name><surname>Ahmed-Farid</surname><given-names>OA</given-names></name><name><surname>Kenawy</surname><given-names>SA</given-names></name></person-group><article-title>The neuroprotective effect of mesenchymal stem cells on an experimentally induced model for multiple sclerosis in mice</article-title><source>J Biochem Mol Toxicol.</source><year>2017</year><pub-id pub-id-type="doi">10.1002/jbt.21936</pub-id><pub-id pub-id-type="pmid">28557239</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cedola</surname><given-names>A</given-names></name><name><surname>Bravin</surname><given-names>A</given-names></name><name><surname>Bukreeva</surname><given-names>I</given-names></name><etal/></person-group><article-title>X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model</article-title><source>Sci Rep.</source><year>2017</year><volume>7</volume><fpage>5890</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-06251-7</pub-id><pub-id pub-id-type="pmid">28724999</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzban</surname><given-names>M</given-names></name><name><surname>Mousavizadeh</surname><given-names>K</given-names></name><name><surname>Bakhshayesh</surname><given-names>M</given-names></name><name><surname>Vousooghi</surname><given-names>N</given-names></name><name><surname>Vakilzadeh</surname><given-names>G</given-names></name><name><surname>Torkaman-Boutorabi</surname><given-names>A</given-names></name></person-group><article-title>Effect of Multiple Intraperitoneal Injections of Human Bone Marrow Mesenchymal Stem Cells on Cuprizone Model of Multiple Sclerosis</article-title><source>Iran. Biomed. J.</source><year>2018</year><volume>22</volume><fpage>312</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.29252/ibj.22.5.312</pub-id><pub-id pub-id-type="pmid">29409311</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><mixed-citation publication-type="other">Kurte M, Luz-Crawford P, Vega-Letter AM, Contreras RA, Tejedor G, Elizondo-Vega R, Martinez-Viola L, Fernandez-O&#x02019;Ryan C, Figueroa FE, Jorgensen C, et al. IL17/IL17RA as a novel signaling axis driving mesenchymal stem cell therapeutic function in experimental autoimmune encephalomyelitis. Front. Immunol. 2018;9:802.</mixed-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>FJ</given-names></name><name><surname>de 
la Fuente</surname><given-names>AG</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Silva</surname><given-names>ME</given-names></name><name><surname>Gonzalez</surname><given-names>GA</given-names></name><name><surname>Wodnar</surname><given-names>R</given-names></name><name><surname>Feichtner</surname><given-names>M</given-names></name><name><surname>Lange</surname><given-names>S</given-names></name><name><surname>Errea</surname><given-names>O</given-names></name><name><surname>Priglinger</surname><given-names>E</given-names></name><name><surname>O'Sullivan</surname><given-names>A</given-names></name><name><surname>Romanelli</surname><given-names>P</given-names></name><name><surname>Jadasz</surname><given-names>JJ</given-names></name><name><surname>Brachtl</surname><given-names>G</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><name><surname>Tempfer</surname><given-names>H</given-names></name><name><surname>Traweger</surname><given-names>A</given-names></name><name><surname>B&#x000e1;tiz</surname><given-names>LF</given-names></name><name><surname>K&#x000fc;ry</surname><given-names>P</given-names></name><name><surname>Couillard-Despres</surname><given-names>S</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name><name><surname>Aigner</surname><given-names>L</given-names></name></person-group><article-title>Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination</article-title><source>Glia.</source><year>2019</year><volume>67</volume><issue>8</issue><fpage>1510</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1002/glia.23624</pub-id><pub-id pub-id-type="pmid">31038798</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barati</surname><given-names>S</given-names></name><name><surname>Kashani</surname><given-names>IR</given-names></name><name><surname>Tahmasebi</surname><given-names>F</given-names></name><name><surname>Mehrabi</surname><given-names>S</given-names></name><name><surname>Joghataei</surname><given-names>MT</given-names></name></person-group><article-title>Effect of mesenchymal stem cells on glial cells population in cuprizone induced demyelination model</article-title><source>Neuropeptides</source><year>2019</year><volume>75</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.npep.2019.04.001</pub-id><pub-id pub-id-type="pmid">31030907</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barati</surname><given-names>S</given-names></name><name><surname>Ragerdi Kashani</surname><given-names>I</given-names></name><name><surname>Moradi</surname><given-names>F</given-names></name><name><surname>Tahmasebi</surname><given-names>F</given-names></name><name><surname>Mehrabi</surname><given-names>S</given-names></name><name><surname>Barati</surname><given-names>M</given-names></name><name><surname>Joghataei</surname><given-names>MT</given-names></name></person-group><article-title>Mesenchymal stem cell mediated effects on microglial phenotype in cuprizone-induced demyelination model</article-title><source>J Cell Biochem.</source><year>2019</year><volume>120</volume><issue>8</issue><fpage>13952</fpage><lpage>13964</lpage><pub-id pub-id-type="doi">10.1002/jcb.28670</pub-id><pub-id pub-id-type="pmid">30963634</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>M</given-names></name></person-group><article-title>Changes of immune parameters of T lymphocytes and macrophages in EAE mice after BM-MSCs transplantation</article-title><source>Immunol. Lett.</source><year>2020</year><volume>225</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2020.05.005</pub-id><pub-id pub-id-type="pmid">32544469</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>GY</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name></person-group><article-title>Mesenchymal Stem Cells Attenuated Blood-Brain Barrier Disruption via Downregulation of Aquaporin-4 Expression in EAE Mice</article-title><source>Mol Neurobiol.</source><year>2020</year><volume>57</volume><issue>9</issue><fpage>3891</fpage><lpage>3901</lpage><pub-id pub-id-type="doi">10.1007/s12035-020-01998-z</pub-id><pub-id pub-id-type="pmid">32613467</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gramlich</surname><given-names>OW</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Godwin</surname><given-names>CR</given-names></name><name><surname>Chimenti</surname><given-names>MS</given-names></name><name><surname>Boland</surname><given-names>LK</given-names></name><name><surname>Ankrum</surname><given-names>JA</given-names></name><name><surname>Kardon</surname><given-names>RH</given-names></name></person-group><article-title>Systemic Mesenchymal Stem Cell Treatment Mitigates Structural and Functional Retinal Ganglion Cell Degeneration in a Mouse Model of Multiple Sclerosis</article-title><source>Transl Vis Sci Technol.</source><year>2020</year><volume>9</volume><issue>8</issue><fpage>16</fpage><pub-id pub-id-type="doi">10.1167/tvst.9.8.16</pub-id><pub-id pub-id-type="pmid">32855863</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Bang</surname><given-names>OY</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Ahn</surname><given-names>YH</given-names></name></person-group><article-title>Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease</article-title><source>J 
Neurochem.</source><year>2008</year><volume>107</volume><issue>1</issue><fpage>141</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05589.x</pub-id><pub-id pub-id-type="pmid">18665911</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchez</surname><given-names>G</given-names></name><name><surname>Senseb&#x000e9;</surname><given-names>L</given-names></name><name><surname>Vourc'h</surname><given-names>P</given-names></name><name><surname>Garreau</surname><given-names>L</given-names></name><name><surname>Bodard</surname><given-names>S</given-names></name><name><surname>Rico</surname><given-names>A</given-names></name><name><surname>Guilloteau</surname><given-names>D</given-names></name><name><surname>Charbord</surname><given-names>P</given-names></name><name><surname>Besnard</surname><given-names>JC</given-names></name><name><surname>Chalon</surname><given-names>S</given-names></name></person-group><article-title>Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease</article-title><source>Neurochem Int.</source><year>2008</year><volume>52</volume><issue>7</issue><fpage>1332</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2008.02.003</pub-id><pub-id pub-id-type="pmid">18372079</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>YX</given-names></name><name><surname>He</surname><given-names>BP</given-names></name><name><surname>Tay</surname><given-names>SSW</given-names></name></person-group><article-title>Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinfammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson&#x02019;s disease</article-title><source>J Neuroimmunol.</source><year>2009</year><volume>216</volume><issue>1</issue><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2009.09.003</pub-id><pub-id pub-id-type="pmid">19819031</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cova</surname><given-names>L</given-names></name><name><surname>Armentero</surname><given-names>MT</given-names></name><name><surname>Zennaro</surname><given-names>E</given-names></name><name><surname>Calzarossa</surname><given-names>C</given-names></name><name><surname>Bossolasco</surname><given-names>P</given-names></name><name><surname>Busca</surname><given-names>G</given-names></name><name><surname>Lambertenghi Deliliers</surname><given-names>G</given-names></name><name><surname>Polli</surname><given-names>E</given-names></name><name><surname>Nappi</surname><given-names>G</given-names></name><name><surname>Silani</surname><given-names>V</given-names></name><name><surname>Blandini</surname><given-names>F</given-names></name></person-group><article-title>Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease</article-title><source>Brain Res.</source><year>2010</year><volume>1311</volume><fpage>12</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2009.11.041</pub-id><pub-id pub-id-type="pmid">19945443</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>EF</given-names></name><name><surname>Gao</surname><given-names>XB</given-names></name><name><surname>Yao</surname><given-names>KV</given-names></name><name><surname>Andrews</surname><given-names>ZB</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Elsworth</surname><given-names>JD</given-names></name><name><surname>Taylor</surname><given-names>HS</given-names></name></person-group><article-title>Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model</article-title><source>J Cell Mol Med.</source><year>2011</year><volume>15</volume><issue>4</issue><fpage>747</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2010.01068.x</pub-id><pub-id pub-id-type="pmid">20406327</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerri</surname><given-names>S</given-names></name><name><surname>Greco</surname><given-names>R</given-names></name><name><surname>Levandis</surname><given-names>G</given-names></name><name><surname>Ghezzi</surname><given-names>C</given-names></name><name><surname>Mangione</surname><given-names>AS</given-names></name><name><surname>Fuzzati-Armentero</surname><given-names>M-T</given-names></name><name><surname>Bonizzi</surname><given-names>A</given-names></name><name><surname>Avanzini</surname><given-names>MA</given-names></name><name><surname>Maccario</surname><given-names>R</given-names></name><name><surname>Blandini</surname><given-names>F</given-names></name></person-group><article-title>Intracarotid infusion of mesenchymal stem cells in an animal model of parkinson&#x02019;s disease, focusing on cell distribution and neuroprotective and behavioral efects</article-title><source>Stem Cells Transl Med.</source><year>2015</year><volume>4</volume><issue>9</issue><fpage>1073</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.5966/sctm.2015-0023</pub-id><pub-id pub-id-type="pmid">26198165</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>EF</given-names></name><name><surname>Mutlu</surname><given-names>L</given-names></name><name><surname>Massasa</surname><given-names>EE</given-names></name><name><surname>Elsworth</surname><given-names>JD</given-names></name><name><surname>Eugene Redmond</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names> HS</given-names></name></person-group><article-title>Endometrial stem cell transplantation in MPTP- exposed primates: an alternative cell source for treatment of Parkinson's disease</article-title><source>J Cell Mol Med.</source><year>2015</year><volume>19</volume><issue>1</issue><fpage>249</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1111/jcmm.12433</pub-id><pub-id pub-id-type="pmid">25283241</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>BN</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>An</surname><given-names>YS</given-names></name></person-group><article-title>Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT</article-title><source>Eur Radiol.</source><year>2015</year><volume>25</volume><issue>5</issue><fpage>1487</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1007/s00330-014-3549-3</pub-id><pub-id pub-id-type="pmid">25504429</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>M</given-names></name><name><surname>Sobh</surname><given-names>M</given-names></name><name><surname>Emam</surname><given-names>M</given-names></name><name><surname>Abdalla</surname><given-names>A</given-names></name><name><surname>Sabry</surname><given-names>D</given-names></name><name><surname>El-Gamal</surname><given-names>M</given-names></name><name><surname>Lotfy</surname><given-names>A</given-names></name><name><surname>El-Husseiny</surname><given-names>M</given-names></name><name><surname>Sobh</surname><given-names>M</given-names></name><name><surname>Shalash</surname><given-names>A</given-names></name></person-group><article-title>Efect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson&#x02019;s disease</article-title><source>Exp Ther Med.</source><year>2017</year><volume>13</volume><issue>3</issue><fpage>976</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.3892/etm.2017.4073</pub-id><pub-id pub-id-type="pmid">28450929</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zhuang</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease</article-title><source>J Neurosci Res.</source><year>2017</year><volume>95</volume><issue>3</issue><fpage>907</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1002/jnr.23879</pub-id><pub-id pub-id-type="pmid">27617772</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Qing</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Synergistic efect of electric stimulation and mesenchymal stem cells against Parkinson&#x02019;s disease</article-title><source>Aging.</source><year>2020</year><volume>12</volume><issue>16</issue><fpage>16062</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.18632/aging.103477</pub-id><pub-id pub-id-type="pmid">32836217</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghahari</surname><given-names>L</given-names></name><name><surname>Safari</surname><given-names>M</given-names></name><name><surname>Rahimi Jaberi</surname><given-names>K</given-names></name><name><surname>Jafari</surname><given-names>B</given-names></name><name><surname>Safari</surname><given-names>K</given-names></name><name><surname>Madadian</surname><given-names>M</given-names></name></person-group><article-title>Mesenchymal stem cells with granulocyte colony-stimulating factor reduce stress oxidative factors in Parkinson&#x02019;s disease</article-title><source>Iran Biomed J.</source><year>2020</year><volume>24</volume><issue>2</issue><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.29252/ibj.24.2.89</pub-id><pub-id pub-id-type="pmid">31677610</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>KA</given-names></name></person-group><article-title>Therapeutic potential of repeated intravenous transplantation of human adipose-derived stem cells in subchronic MPTP-induced Parkinson&#x02019;s disease mouse model</article-title><source>Int J Mol Sci.</source><year>2020</year><volume>21</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.3390/ijms21218129</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><mixed-citation publication-type="other">Jalali MS, Sarkaki A, Farbood Y, Azandeh SS, Mansouri E, Ghasemi Dehcheshmeh M, Saki G. Transplanted Wharton&#x02019;s jelly mesenchymal stem cells improve memory and brain hippocampal electrophysiology in rat model of Parkinson&#x02019;s disease. J Chem Neuroanat. 2020;110.</mixed-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SS</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Mesenchymal Stem Cell-Derived Extracellular Vesicles Suppresses iNOS Expression and Ameliorates Neural Impairment in Alzheimer's Disease Mice</article-title><source>J Alzheimers Dis.</source><year>2018</year><volume>61</volume><issue>3</issue><fpage>1005</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.3233/JAD-170848</pub-id><pub-id pub-id-type="pmid">29254100</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>GH</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Mou</surname><given-names>FF</given-names></name><name><surname>Xie</surname><given-names>WH</given-names></name><name><surname>Wang</surname><given-names>FB</given-names></name><name><surname>Wang</surname><given-names>QL</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>YW</given-names></name><name><surname>Dong</surname><given-names>YR</given-names></name><name><surname>Liu</surname><given-names>JR</given-names></name><name><surname>Guo</surname><given-names>HD</given-names></name></person-group><article-title>Exosomes derived from hypoxia-preconditioned mesenchymal stromal cells ameliorate cognitive decline by rescuing synaptic dysfunction and regulating inflammatory responses in APP/PS1 mice</article-title><source>FASEB 
J.</source><year>2018</year><volume>32</volume><issue>2</issue><fpage>654</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1096/fj.201700600R</pub-id><pub-id pub-id-type="pmid">28970251</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lyu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Bi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><article-title>Exosomes Isolated From Human Umbilical Cord Mesenchymal Stem Cells Alleviate Neuroinflammation and Reduce Amyloid-Beta Deposition by Modulating Microglial Activation in Alzheimer's Disease</article-title><source>Neurochem Res.</source><year>2018</year><volume>43</volume><issue>11</issue><fpage>2165</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.1007/s11064-018-2641-5</pub-id><pub-id pub-id-type="pmid">30259257</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elia</surname><given-names>CA</given-names></name><name><surname>Tamborini</surname><given-names>M</given-names></name><name><surname>Rasile</surname><given-names>M</given-names></name><name><surname>Desiato</surname><given-names>G</given-names></name><name><surname>Marchetti</surname><given-names>S</given-names></name><name><surname>Swuec</surname><given-names>P</given-names></name><name><surname>Mazzitelli</surname><given-names>S</given-names></name><name><surname>Clemente</surname><given-names>F</given-names></name><name><surname>Anselmo</surname><given-names>A</given-names></name><name><surname>Matteoli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intracerebral Injection of Extracellular Vesicles from Mesenchymal Stem Cells Exerts Reduced A&#x003b2; Plaque Burden in Early Stages of a Preclinical Model of Alzheimer&#x02019;s Disease</article-title><source>Cells</source><year>2019</year><volume>8</volume><fpage>1059</fpage><pub-id pub-id-type="doi">10.3390/cells8091059</pub-id><pub-id pub-id-type="pmid">31510042</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><article-title>An experimental study on the treatment of diabetes-induced cognitive disorder mice model with exosomes deriving from mesenchymal stem cells (MSCs)</article-title><source>Pak J Pharm Sci</source><year>2019</year><volume>32</volume><fpage>1965</fpage><lpage>1970</lpage><pub-id pub-id-type="pmid">31813859</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reza-Zaldivar</surname><given-names>EE</given-names></name><name><surname>Hern&#x000e1;ndez-Sapi&#x000e9;ns</surname><given-names>MA</given-names></name><name><surname>Guti&#x000e9;rrez-Mercado</surname><given-names>YK</given-names></name><name><surname>Sandoval-&#x000c1;vila</surname><given-names>S</given-names></name><name><surname>Gomez-Pinedo</surname><given-names>U</given-names></name><name><surname>M&#x000e1;rquezAguirre</surname><given-names>AL</given-names></name><name><surname>V&#x000e1;zquez-M&#x000e9;ndez</surname><given-names>E</given-names></name><name><surname>Padilla-Camberos</surname><given-names>E</given-names></name><name><surname>Canales-Aguirre</surname><given-names>AA</given-names></name></person-group><article-title>Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer&#x02019;s disease</article-title><source>Neural. Regen Res.</source><year>2019</year><volume>14</volume><fpage>1626</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.255978</pub-id><pub-id pub-id-type="pmid">31089063</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reza-Zaldivar</surname><given-names>EE</given-names></name><name><surname>Hern&#x000e1;ndez-Sapi&#x000e9;ns</surname><given-names>MA</given-names></name><name><surname>Guti&#x000e9;rrez-Mercado</surname><given-names>YK</given-names></name><name><surname>Sandoval-&#x000c1;vila</surname><given-names>S</given-names></name><name><surname>Gomez-Pinedo</surname><given-names>U</given-names></name><name><surname>M&#x000e1;rquez-Aguirre</surname><given-names>AL</given-names></name><name><surname>V&#x000e1;zquez-M&#x000e9;ndez</surname><given-names>E</given-names></name><name><surname>Padilla-Camberos</surname><given-names>E</given-names></name><name><surname>Canales-Aguirre</surname><given-names>AA</given-names></name></person-group><article-title>Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer&#x02019;s disease</article-title><source>Neural Regen. Res.</source><year>2019</year><volume>14</volume><fpage>1626</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.255978</pub-id><pub-id pub-id-type="pmid">31089063</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name></person-group><article-title>Bone marrow mesenchymal stem cells-derived exosomes reduce A&#x003b2; deposition and improve cognitive function recovery in mice with Alzheimer's disease by activating sphingosine kinase/sphingosine-1-phosphate signaling pathway</article-title><source>Cell Biol Int.</source><year>2021</year><volume>45</volume><issue>4</issue><fpage>775</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1002/cbin.11522</pub-id><pub-id pub-id-type="pmid">33300254</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Q
</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><etal/></person-group><article-title>ADSCs-derived extracellular vesicles alleviate neuronal damage, promote neurogenesis and rescue memory loss in mice with Alzheimer&#x02019;s disease</article-title><source>J Control Release</source><year>2020</year><volume>327</volume><fpage>688</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.09.019</pub-id><pub-id pub-id-type="pmid">32931898</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Losurdo</surname><given-names>M</given-names></name><name><surname>Pedrazzoli</surname><given-names>M</given-names></name><name><surname>D'Agostino</surname><given-names>C</given-names></name><etal/></person-group><article-title>Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer's disease</article-title><source>STEM CELLS Trans Med</source><year>2020</year><volume>9</volume><issue>9</issue><fpage>1068</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1002/sctm.19-0327</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><mixed-citation publication-type="other">Hassan R, Rabea AA, Ragae A, Sabry D. The prospective role of mesenchymal stem cells exosomes on circumvallate taste buds in induced Alzheimer&#x02019;s disease of ovariectomized albino rats: (Light and transmission electron microscopic study). Arch Oral Biol. 2020;110.</mixed-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Shan</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name></person-group><article-title>Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia</article-title><source>Int. Immunopharmacol.</source><year>2019</year><volume>67</volume><fpage>268</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2018.12.001</pub-id><pub-id pub-id-type="pmid">30572251</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riazifar</surname><given-names>M</given-names></name><name><surname>Mohammadi</surname><given-names>MR</given-names></name><name><surname>Pone</surname><given-names>EJ</given-names></name><name><surname>Yeri</surname><given-names>A</given-names></name><name><surname>L&#x000e4;sser</surname><given-names>C</given-names></name><name><surname>Segaliny</surname><given-names>AI</given-names></name><name><surname>McIntyre</surname><given-names>LL</given-names></name><name><surname>Shelke</surname><given-names>GV</given-names></name><name><surname>Hutchins</surname><given-names>E</given-names></name><name><surname>Hamamoto</surname><given-names>A</given-names></name><name><surname>Calle</surname><given-names>EN</given-names></name><name><surname>Crescitelli</surname><given-names>R</given-names></name><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Pham</surname><given-names>V</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Jayaraman</surname><given-names>J</given-names></name><name><surname>Lakey</surname><given-names>JRT</given-names></name><name><surname>Walsh</surname><given-names>CM</given-names></name><name><surname>Van Keuren-Jensen</surname><given-names>K</given-names></name><name><surname>Lotvall</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name></person-group><article-title>Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders</article-title><source>ACS Nano.</source><year>2019</year><volume>13</volume><issue>6</issue><fpage>6670</fpage><lpage>6688</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b01004</pub-id><pub-id pub-id-type="pmid">31117376</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Carvalho</surname><given-names>MM</given-names></name><name><surname>Panchalingam</surname><given-names>KM</given-names></name><name><surname>Rodrigues</surname><given-names>AJ</given-names></name><name><surname>Mendes-Pinheiro</surname><given-names>B</given-names></name><name><surname>Anjo</surname><given-names>S</given-names></name><name><surname>Manadas</surname><given-names>B</given-names></name><name><surname>Behie</surname><given-names>LA</given-names></name><name><surname>Sousa</surname><given-names>N</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name></person-group><article-title>Impact of the secretome of human mesenchymal stem cells on brain structure and animal behavior in a rat model of Parkinson&#x02019;s disease</article-title><source>Stem Cells Transl Med.</source><year>2017</year><volume>6</volume><issue>2</issue><fpage>634</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.5966/sctm.2016-0071</pub-id><pub-id pub-id-type="pmid">28191785</pub-id></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chierchia</surname><given-names>A</given-names></name><name><surname>Chirico</surname><given-names>N</given-names></name><name><surname>Boeri</surname><given-names>L</given-names></name><name><surname>Raimondi</surname><given-names>I</given-names></name><name><surname>Riva</surname><given-names>GA</given-names></name><name><surname>Raimondi</surname><given-names>MT</given-names></name><name><surname>Tunesi</surname><given-names>M</given-names></name><name><surname>Giordano</surname><given-names>C</given-names></name><name><surname>Forloni</surname><given-names>G</given-names></name><name><surname>Albani</surname><given-names>D</given-names></name></person-group><article-title>Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson&#x02019;s disease related toxin 6-hydroxydopamine</article-title><source>Eur J Pharma Biopharm.</source><year>2017</year><volume>121</volume><fpage>113</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2017.09.014</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendes-Pinheiro</surname><given-names>B</given-names></name><name><surname>Anjo</surname><given-names>SI</given-names></name><name><surname>Manadas</surname><given-names>B</given-names></name><name><surname>Da Silva</surname><given-names>JD</given-names></name><name><surname>Marote</surname><given-names>A</given-names></name><name><surname>Behie</surname><given-names>LA</given-names></name><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name></person-group><article-title>Bone marrow mesenchymal stem cells&#x02019; secretome exerts neuroprotective efects in a Parkinson&#x02019;s disease rat model</article-title><source>Front Bioeng Biotechnol.</source><year>2019</year><volume>7</volume><fpage>294</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2019.00294</pub-id><pub-id pub-id-type="pmid">31737616</pub-id></element-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giamp&#x000e0;</surname><given-names>C</given-names></name><name><surname>Alvino</surname><given-names>A</given-names></name><name><surname>Magatti</surname><given-names>M</given-names></name><name><surname>Silini</surname><given-names>AR</given-names></name><name><surname>Cardinale</surname><given-names>A</given-names></name><name><surname>Paldino</surname><given-names>E</given-names></name><name><surname>Fusco</surname><given-names>FR</given-names></name><name><surname>Parolini</surname><given-names>O</given-names></name></person-group><article-title>Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor defcits in the R6/2 mouse model of Huntington&#x02019;s disease</article-title><source>J Cell Mol Med.</source><year>2019</year><volume>23</volume><issue>2</issue><fpage>1581</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1111/jcmm.14113</pub-id><pub-id pub-id-type="pmid">30585395</pub-id></element-citation></ref><ref id="CR212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HX</given-names></name><name><surname>Liang</surname><given-names>FC</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>BL</given-names></name><name><surname>Xu</surname><given-names>HJ</given-names></name><name><surname>Wang</surname><given-names>WT</given-names></name><name><surname>Hou</surname><given-names>JY</given-names></name><name><surname>Xie</surname><given-names>DX</given-names></name><name><surname>Chai</surname><given-names>XQ</given-names></name><name><surname>An</surname><given-names>SJ</given-names></name></person-group><article-title>Exosomes derived from mesenchymal stem cells repair a Parkinson&#x02019;s disease model by inducing autophagy</article-title><source>Cell Death Dis.</source><year>2020</year><volume>11</volume><fpage>288</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-2473-5</pub-id><pub-id pub-id-type="pmid">32341347</pub-id></element-citation></ref><ref id="CR213"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Vila&#x000e7;a-Faria</surname><given-names>H</given-names></name><name><surname>Domingues</surname><given-names>AV</given-names></name><name><surname>Campos</surname><given-names>J</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name></person-group><article-title>Preclinical comparison of stem cells secretome and levodopa application in a 6-hydroxydopamine rat model of Parkinson&#x02019;s disease</article-title><source>Cells.</source><year>2020</year><volume>9</volume><issue>2</issue><fpage>315</fpage><pub-id pub-id-type="doi">10.3390/cells9020315</pub-id><pub-id pub-id-type="pmid">32012897</pub-id></element-citation></ref><ref id="CR214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xing</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name></person-group><article-title>Exosomes derived from miR-188-3p-modifed adipose-derived mesenchymal stem cells protect Parkinson&#x02019;s disease</article-title><source>Mol Ther Nucleic Acids.</source><year>2021</year><volume>23</volume><fpage>1334</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2021.01.022</pub-id><pub-id pub-id-type="pmid">33717653</pub-id></element-citation></ref><ref id="CR215"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ba</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>RC</given-names></name></person-group><article-title>MSC-derived exosomes can enhance the angiogenesis of human brain MECs and show therapeutic potential in a mouse model of Parkinson&#x02019;s disease</article-title><source>Aging Dis.</source><year>2021</year><volume>12</volume><issue>5</issue><fpage>1211</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.14336/AD.2020.1221</pub-id><pub-id pub-id-type="pmid">34341703</pub-id></element-citation></ref><ref id="CR216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>CR</given-names></name><name><surname>Pereira-Sousa</surname><given-names>J</given-names></name><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Sousa</surname><given-names>RA</given-names></name><name><surname>Teixeira-Castro</surname><given-names>A</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name></person-group><article-title>Mesenchymal stem cell secretome protects against alpha-synuclein-induced neurodegeneration in a Caenorhabditis elegans model of Parkinson&#x02019;s disease</article-title><source>Cytotherapy.</source><year>2021</year><volume>23</volume><issue>10</issue><fpage>894</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2021.04.002</pub-id><pub-id pub-id-type="pmid">34059421</pub-id></element-citation></ref><ref id="CR217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marote</surname><given-names>A</given-names></name><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Mendes-Pinheiro</surname><given-names>B</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name></person-group><article-title>MSCs-Derived Exosomes: Cell-Secreted Nanovesicles with Regenerative Potential</article-title><source>Front Pharmacol.</source><year>2016</year><volume>7</volume><fpage>231</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00231</pub-id><pub-id pub-id-type="pmid">27536241</pub-id></element-citation></ref><ref id="CR218"><label>218.</label><mixed-citation publication-type="other">Chaput N, Th&#x000e9;ry C. Exosomes: immune properties and potential clinical implementations. In Seminars in immunopathology, vol. 33. 2011; Springer-Verlag, pp. 419&#x02013;40</mixed-citation></ref><ref id="CR219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorabi</surname><given-names>AM</given-names></name><name><surname>Kiaie</surname><given-names>N</given-names></name><name><surname>Barreto</surname><given-names>GE</given-names></name><name><surname>Read</surname><given-names>MI</given-names></name><name><surname>Tafti</surname><given-names>HA</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name></person-group><article-title>The Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in Treatment of Neurodegenerative Diseases</article-title><source>Mol Neurobiol.</source><year>2019</year><volume>56</volume><issue>12</issue><fpage>8157</fpage><lpage>8167</lpage><pub-id pub-id-type="doi">10.1007/s12035-019-01663-0</pub-id><pub-id pub-id-type="pmid">31197655</pub-id></element-citation></ref><ref id="CR220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKelvey</surname><given-names>KJ</given-names></name><name><surname>Powell</surname><given-names>KL</given-names></name><name><surname>Ashton</surname><given-names>AW</given-names></name><name><surname>Morris</surname><given-names>JM</given-names></name><name><surname>McCracken</surname><given-names>SA</given-names></name></person-group><article-title>Exosomes: Mechanisms of Uptake</article-title><source>J Circ Biomark.</source><year>2015</year><volume>4</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.5772/61186</pub-id><pub-id pub-id-type="pmid">28936243</pub-id></element-citation></ref><ref id="CR221"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name></person-group><article-title>Pre-conditioned mesenchymal stem cells: a better way for cell-based therapy</article-title><source>Stem Cell Res Ther.</source><year>2013</year><volume>4</volume><issue>3</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1186/scrt213</pub-id><pub-id pub-id-type="pmid">23290259</pub-id></element-citation></ref><ref id="CR222"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redondo-Castro</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Martuscelli</surname><given-names>L</given-names></name><name><surname>Aoulad-Ali</surname><given-names>S</given-names></name><name><surname>Rothwell</surname><given-names>NJ</given-names></name><name><surname>Kielty</surname><given-names>CM</given-names></name><name><surname>Allan</surname><given-names>SM</given-names></name><name><surname>Pinteaux</surname><given-names>E</given-names></name></person-group><article-title>Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro</article-title><source>Stem Cell Res Ther.</source><year>2017</year><volume>8</volume><issue>1</issue><fpage>79</fpage><pub-id pub-id-type="doi">10.1186/s13287-017-0531-4</pub-id><pub-id pub-id-type="pmid">28412968</pub-id></element-citation></ref><ref id="CR223"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahbaran</surname><given-names>M</given-names></name><name><surname>Zekiy</surname><given-names>AO</given-names></name><name><surname>Bahramali</surname><given-names>M</given-names></name><name><surname>Jahangir</surname><given-names>M</given-names></name><name><surname>Mardasi</surname><given-names>M</given-names></name><name><surname>Sakhaei</surname><given-names>D</given-names></name><name><surname>Thangavelu</surname><given-names>L</given-names></name><name><surname>Shomali</surname><given-names>N</given-names></name><name><surname>Zamani</surname><given-names>M</given-names></name><name><surname>Mohammadi</surname><given-names>A</given-names></name><name><surname>Rahnama</surname><given-names>N</given-names></name></person-group><article-title>Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects</article-title><source>Cell Mol Biol Lett.</source><year>2022</year><volume>27</volume><issue>1</issue><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s11658-022-00359-z</pub-id><pub-id pub-id-type="pmid">35842587</pub-id></element-citation></ref><ref id="CR224"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Panchalingam</surname><given-names>KM</given-names></name><name><surname>Assun&#x000e7;&#x000e3;o-Silva</surname><given-names>R</given-names></name><name><surname>Serra</surname><given-names>SC</given-names></name><name><surname>Mendes-Pinheiro</surname><given-names>B</given-names></name><name><surname>Patr&#x000ed;cio</surname><given-names>P</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Anjo</surname><given-names>SI</given-names></name><name><surname>Manadas</surname><given-names>B</given-names></name><name><surname>Pinto</surname><given-names>L</given-names></name><name><surname>Sousa</surname><given-names>N</given-names></name><name><surname>Behie</surname><given-names>LA</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name></person-group><article-title>Modulation of the Mesenchymal Stem Cell Secretome Using Computer-Controlled Bioreactors: Impact on Neuronal Cell Proliferation</article-title><source>Survival and Differentiation. Sci Rep.</source><year>2016</year><volume>6</volume><fpage>27791</fpage><pub-id pub-id-type="doi">10.1038/srep27791</pub-id><pub-id pub-id-type="pmid">27301770</pub-id></element-citation></ref><ref id="CR225"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>FG</given-names></name><name><surname>Panchalingam</surname><given-names>KM</given-names></name><name><surname>Anjo</surname><given-names>SI</given-names></name><name><surname>Manadas</surname><given-names>B</given-names></name><name><surname>Pereira</surname><given-names>R</given-names></name><name><surname>Sousa</surname><given-names>N</given-names></name><name><surname>Salgado</surname><given-names>AJ</given-names></name><name><surname>Behie</surname><given-names>LA</given-names></name></person-group><article-title>Do hypoxia/normoxia culturing conditions change the neuroregulatory profile of Wharton Jelly mesenchymal stem cell secretome?</article-title><source>Stem Cell Res Ther.</source><year>2015</year><volume>6</volume><issue>1</issue><fpage>133</fpage><pub-id pub-id-type="doi">10.1186/s13287-015-0124-z</pub-id><pub-id pub-id-type="pmid">26204925</pub-id></element-citation></ref></ref-list></back></article>